US20030003520A1 - FXR receptor-mediated modulation of cholesterol metabolism - Google Patents
FXR receptor-mediated modulation of cholesterol metabolism Download PDFInfo
- Publication number
- US20030003520A1 US20030003520A1 US10/217,293 US21729302A US2003003520A1 US 20030003520 A1 US20030003520 A1 US 20030003520A1 US 21729302 A US21729302 A US 21729302A US 2003003520 A1 US2003003520 A1 US 2003003520A1
- Authority
- US
- United States
- Prior art keywords
- fxr
- accordance
- ligand
- cell
- binding domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 125
- 102100038495 Bile acid receptor Human genes 0.000 title claims abstract description 33
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 title claims abstract description 31
- 230000004060 metabolic process Effects 0.000 title claims abstract description 31
- 230000001404 mediated effect Effects 0.000 title abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 134
- 150000001875 compounds Chemical class 0.000 claims abstract description 112
- 239000003446 ligand Substances 0.000 claims abstract description 89
- 230000014509 gene expression Effects 0.000 claims abstract description 78
- 238000009739 binding Methods 0.000 claims abstract description 64
- 230000027455 binding Effects 0.000 claims abstract description 63
- 239000003613 bile acid Substances 0.000 claims abstract description 58
- 238000012360 testing method Methods 0.000 claims abstract description 46
- 239000003814 drug Substances 0.000 claims abstract description 32
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 26
- 108010060434 Co-Repressor Proteins Proteins 0.000 claims abstract description 16
- 102000008169 Co-Repressor Proteins Human genes 0.000 claims abstract description 16
- 241000124008 Mammalia Species 0.000 claims abstract description 15
- 210000004027 cell Anatomy 0.000 claims description 147
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 138
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 105
- 229920001184 polypeptide Polymers 0.000 claims description 98
- 238000003556 assay Methods 0.000 claims description 65
- 230000004568 DNA-binding Effects 0.000 claims description 57
- 108020001756 ligand binding domains Proteins 0.000 claims description 56
- 108091027981 Response element Proteins 0.000 claims description 47
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 claims description 45
- 102000005962 receptors Human genes 0.000 claims description 33
- 108020003175 receptors Proteins 0.000 claims description 33
- 108700008625 Reporter Genes Proteins 0.000 claims description 26
- 101150012100 cyp7 gene Proteins 0.000 claims description 24
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 23
- 238000002875 fluorescence polarization Methods 0.000 claims description 22
- 102100039556 Galectin-4 Human genes 0.000 claims description 19
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims description 19
- 230000001965 increasing effect Effects 0.000 claims description 19
- 150000001413 amino acids Chemical group 0.000 claims description 17
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 claims description 16
- 230000003081 coactivator Effects 0.000 claims description 16
- 238000012216 screening Methods 0.000 claims description 16
- 230000007423 decrease Effects 0.000 claims description 15
- 102000040430 polynucleotide Human genes 0.000 claims description 13
- 108091033319 polynucleotide Proteins 0.000 claims description 13
- 239000002157 polynucleotide Substances 0.000 claims description 13
- 238000013518 transcription Methods 0.000 claims description 11
- 230000035897 transcription Effects 0.000 claims description 11
- 108090001146 Nuclear Receptor Coactivator 1 Proteins 0.000 claims description 10
- 102100037223 Nuclear receptor coactivator 1 Human genes 0.000 claims description 10
- 230000003247 decreasing effect Effects 0.000 claims description 7
- GHCZAUBVMUEKKP-GYPHWSFCSA-N glycochenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 GHCZAUBVMUEKKP-GYPHWSFCSA-N 0.000 claims description 7
- 108020004414 DNA Proteins 0.000 claims description 6
- 238000002965 ELISA Methods 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 238000011144 upstream manufacturing Methods 0.000 claims description 6
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 239000011541 reaction mixture Substances 0.000 claims description 4
- BHTRKEVKTKCXOH-BJLOMENOSA-N taurochenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-BJLOMENOSA-N 0.000 claims description 4
- 102000004217 thyroid hormone receptors Human genes 0.000 claims description 4
- 108090000721 thyroid hormone receptors Proteins 0.000 claims description 4
- 238000000159 protein binding assay Methods 0.000 claims description 3
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- 108010080146 androgen receptors Proteins 0.000 claims description 2
- 108010038795 estrogen receptors Proteins 0.000 claims description 2
- 239000002395 mineralocorticoid Substances 0.000 claims description 2
- 108090000468 progesterone receptors Proteins 0.000 claims description 2
- 108091008679 retinoid hormone receptors Proteins 0.000 claims description 2
- 102000027483 retinoid hormone receptors Human genes 0.000 claims description 2
- 102000009310 vitamin D receptors Human genes 0.000 claims description 2
- 108050000156 vitamin D receptors Proteins 0.000 claims description 2
- 102100032187 Androgen receptor Human genes 0.000 claims 1
- 102100038595 Estrogen receptor Human genes 0.000 claims 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 claims 1
- 102100025803 Progesterone receptor Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 67
- 230000000694 effects Effects 0.000 abstract description 59
- 239000000203 mixture Substances 0.000 abstract description 17
- 238000000099 in vitro assay Methods 0.000 abstract description 5
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 41
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 39
- 239000013612 plasmid Substances 0.000 description 39
- 150000007523 nucleic acids Chemical class 0.000 description 35
- 108060001084 Luciferase Proteins 0.000 description 34
- 102000039446 nucleic acids Human genes 0.000 description 33
- 108020004707 nucleic acids Proteins 0.000 description 33
- 239000005089 Luciferase Substances 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 32
- 235000018102 proteins Nutrition 0.000 description 31
- 108700010039 chimeric receptor Proteins 0.000 description 30
- 108090000943 Cholesterol 7-alpha-monooxygenases Proteins 0.000 description 27
- 102000004410 Cholesterol 7-alpha-monooxygenases Human genes 0.000 description 27
- 230000001629 suppression Effects 0.000 description 24
- 235000012000 cholesterol Nutrition 0.000 description 19
- 239000013598 vector Substances 0.000 description 19
- 102000037865 fusion proteins Human genes 0.000 description 16
- 108020001507 fusion proteins Proteins 0.000 description 16
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 15
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 15
- 239000000370 acceptor Substances 0.000 description 15
- -1 isoprenoid lipids Chemical class 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 14
- 239000013604 expression vector Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 13
- 108020004017 nuclear receptors Proteins 0.000 description 12
- 230000003321 amplification Effects 0.000 description 11
- 230000003993 interaction Effects 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 238000003199 nucleic acid amplification method Methods 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 208000035150 Hypercholesterolemia Diseases 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 10
- 230000004927 fusion Effects 0.000 description 10
- 102100026189 Beta-galactosidase Human genes 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 108010005774 beta-Galactosidase Proteins 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000003752 polymerase chain reaction Methods 0.000 description 9
- 238000010367 cloning Methods 0.000 description 8
- 108090000865 liver X receptors Proteins 0.000 description 8
- 102000004311 liver X receptors Human genes 0.000 description 8
- 238000010791 quenching Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108010038912 Retinoid X Receptors Proteins 0.000 description 7
- 102000034527 Retinoid X Receptors Human genes 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 6
- 239000007850 fluorescent dye Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 6
- 230000000171 quenching effect Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 5
- 229960003964 deoxycholic acid Drugs 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000007423 screening assay Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108010035533 Drosophila Proteins Proteins 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 108010015031 Glycochenodeoxycholic Acid Proteins 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 229940049706 benzodiazepine Drugs 0.000 description 4
- 150000001557 benzodiazepines Chemical class 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- 102000005969 steroid hormone receptors Human genes 0.000 description 4
- 108020003113 steroid hormone receptors Proteins 0.000 description 4
- GHCZAUBVMUEKKP-UHFFFAOYSA-N ursodeoxycholic acid glycine-conjugate Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)CC2 GHCZAUBVMUEKKP-UHFFFAOYSA-N 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010001515 Galectin 4 Proteins 0.000 description 3
- 101100405131 Homo sapiens NR5A2 gene Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000031154 cholesterol homeostasis Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000000295 emission spectrum Methods 0.000 description 3
- 230000005281 excited state Effects 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 238000003159 mammalian two-hybrid assay Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
- OSENKJZWYQXHBN-UHFFFAOYSA-N (3beta,24S)-24,25-Epoxycholest-5-en-3-ol Natural products C1CC2C3CC=C4CC(O)CCC4(C)C3CCC2(C)C1C(C)CCC1OC1(C)C OSENKJZWYQXHBN-UHFFFAOYSA-N 0.000 description 2
- OSENKJZWYQXHBN-XVYZBDJZSA-N 24(S),25-epoxycholesterol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2CC1)C)C[C@@H]1OC1(C)C OSENKJZWYQXHBN-XVYZBDJZSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108070000005 Bile acid receptors Proteins 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- 241000252212 Danio rerio Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108010007979 Glycocholic Acid Proteins 0.000 description 2
- 102000006752 Hepatocyte Nuclear Factor 4 Human genes 0.000 description 2
- 101150068639 Hnf4a gene Proteins 0.000 description 2
- 101001093899 Homo sapiens Retinoic acid receptor RXR-alpha Proteins 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 102000000853 LDL receptors Human genes 0.000 description 2
- 108010001831 LDL receptors Proteins 0.000 description 2
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 102100022679 Nuclear receptor subfamily 4 group A member 1 Human genes 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 102100035178 Retinoic acid receptor RXR-alpha Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229920000080 bile acid sequestrant Polymers 0.000 description 2
- 238000010256 biochemical assay Methods 0.000 description 2
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 108010057988 ecdysone receptor Proteins 0.000 description 2
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 2
- 229940099347 glycocholic acid Drugs 0.000 description 2
- 108091008634 hepatocyte nuclear factors 4 Proteins 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 150000002611 lead compounds Chemical class 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 230000030648 nucleus localization Effects 0.000 description 2
- 102000004164 orphan nuclear receptors Human genes 0.000 description 2
- 108090000629 orphan nuclear receptors Proteins 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 238000006862 quantum yield reaction Methods 0.000 description 2
- 230000000754 repressing effect Effects 0.000 description 2
- 150000004492 retinoid derivatives Chemical class 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 238000003151 transfection method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 description 1
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- SJQRQOKXQKVJGJ-UHFFFAOYSA-N 5-(2-aminoethylamino)naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1S(O)(=O)=O SJQRQOKXQKVJGJ-UHFFFAOYSA-N 0.000 description 1
- ZMERMCRYYFRELX-UHFFFAOYSA-N 5-{[2-(iodoacetamido)ethyl]amino}naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1NCCNC(=O)CI ZMERMCRYYFRELX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001578974 Achlya <moth> Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100034044 All-trans-retinol dehydrogenase [NAD(+)] ADH1B Human genes 0.000 description 1
- 101710193111 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000713840 Avian erythroblastosis virus Species 0.000 description 1
- 241000589151 Azotobacter Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 241000251538 Branchiostoma lanceolatum Species 0.000 description 1
- 241000208199 Buxus sempervirens Species 0.000 description 1
- 108010020650 COUP Transcription Factor II Proteins 0.000 description 1
- 102000008523 COUP Transcription Factor II Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241001619326 Cephalosporium Species 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 241000228437 Cochliobolus Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 108700037220 Drosophila Hr3 Proteins 0.000 description 1
- 108700004755 Drosophila knrl Proteins 0.000 description 1
- 101000638921 Drosophila melanogaster Protein ultraspiracle Proteins 0.000 description 1
- 102000006490 Eicosanoid receptors Human genes 0.000 description 1
- 108010019316 Eicosanoid receptors Proteins 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000957672 Homo sapiens Cytochrome P450 7A1 Proteins 0.000 description 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
- 101001010910 Homo sapiens Estrogen receptor beta Proteins 0.000 description 1
- 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 101100405117 Homo sapiens NR4A1 gene Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100119135 Mus musculus Esrrb gene Proteins 0.000 description 1
- 101100460844 Mus musculus Nr2f6 gene Proteins 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 101100285000 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) his-3 gene Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 101150012394 PHO5 gene Proteins 0.000 description 1
- 241001057811 Paracoccus <mealybug> Species 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000221945 Podospora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241001415846 Procellariidae Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000231139 Pyricularia Species 0.000 description 1
- BDJDTKYGKHEMFF-UHFFFAOYSA-M QSY7 succinimidyl ester Chemical compound [Cl-].C=1C=C2C(C=3C(=CC=CC=3)S(=O)(=O)N3CCC(CC3)C(=O)ON3C(CCC3=O)=O)=C3C=C\C(=[N+](\C)C=4C=CC=CC=4)C=C3OC2=CC=1N(C)C1=CC=CC=C1 BDJDTKYGKHEMFF-UHFFFAOYSA-M 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 101001109695 Rattus norvegicus Nuclear receptor subfamily 4 group A member 1 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 101100186386 Schizosaccharomyces pombe (strain 972 / ATCC 24843) nak1 gene Proteins 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 101150006914 TRP1 gene Proteins 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000863000 Vitreoscilla Species 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003858 bile acid conjugate Substances 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 108091006116 chimeric peptides Proteins 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960002997 dehydrocholic acid Drugs 0.000 description 1
- LABSLXOWZIMSBL-UHFFFAOYSA-N dehydrodiooniferyl alcohol Natural products O1C=2C(OC)=CC(C=CCOC)=CC=2C(CO)C1C1=CC=C(O)C=C1 LABSLXOWZIMSBL-UHFFFAOYSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- GWQVMPWSEVRGPY-UHFFFAOYSA-N europium cryptate Chemical compound [Eu+3].N=1C2=CC=CC=1CN(CC=1N=C(C=CC=1)C=1N=C(C3)C=CC=1)CC(N=1)=CC(C(=O)NCCN)=CC=1C(N=1)=CC(C(=O)NCCN)=CC=1CN3CC1=CC=CC2=N1 GWQVMPWSEVRGPY-UHFFFAOYSA-N 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 238000000198 fluorescence anisotropy Methods 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- 102000052152 human CYP7A1 Human genes 0.000 description 1
- 108700013139 human ERD5 Proteins 0.000 description 1
- 102000047486 human GAPDH Human genes 0.000 description 1
- 102000011941 human estrogen receptor alpha Human genes 0.000 description 1
- 150000001469 hydantoins Chemical class 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000004322 lipid homeostasis Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 238000002761 liquid phase assay Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108010094020 polyglycine Proteins 0.000 description 1
- 229920000232 polyglycine polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 239000006176 redox buffer Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- BHTRKEVKTKCXOH-AYSJQVDDSA-N taurochenodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)C1C2C2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-AYSJQVDDSA-N 0.000 description 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 108091006108 transcriptional coactivators Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
Definitions
- This invention relates to methods and compounds for the modulation of cholesterol metabolism in a mammal and methods for screening to identify candidate therapeutic agents for modulation of cholesterol levels.
- Atherosclerosis is a leading cause of death, myocardial infarctions, stroke, peripheral vascular disease and cardiovascular disease (Libby, in Chapter 242 of Harrison 's Principles of Internal Medicine, 14th edition (1998) (Fauci et al., eds.); Witztum, in Chapter 36 of Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th edition (1996) (Hardman et al., eds.)).
- hypercholesterolemia is currently treated with a combination of dietary and pharmaceutical therapies. Often more than a single pharmaceutical agent and a dietary regimen are necessary to decrease total cholesterol and LDL cholesterol levels to the desired level.
- niacin Drugs such as bile acid sequestrants, niacin and the statins are commonly used to treat hypercholesterolemia and atherosclerosis.
- the use of niacin is limited by the high incidence (>50%) of numerous side effects that are experienced in patients. Thus, a need for therapeutic agents that would decrease cholesterol levels still exists.
- Cholesterol homeostasis in mammals is maintained through the coordinate regulation of three major pathways in the liver.
- Two pathways supply cholesterol to cells and include an endogenous biosynthetic pathway in which acetate is converted into cholesterol and an exogenous pathway in which members of the low-density lipoprotein receptor family bind and internalize cholesterol-carrying particles from the blood.
- a third pathway involves the conversion of cholesterol into hydrophilic bile acids.
- the conversion of cholesterol to bile acids involves a minimum of fourteen enzymes of the bile acid biosynthetic pathway.
- the first and rate-limiting enzymatic reaction of this pathway is catalyzed by the enzyme cholesterol 7 ⁇ -hydrolase.
- the cholesterol 7 ⁇ -hydrolase gene also known as cyp7A, belong to the cytochrome P-450 family that contains many microsomal enzymes involved in liver metabolism. It has been shown that expression of the cyp7A gene is tightly regulated. This gene is expressed exclusively in the liver and its expression can be induced by dietary cholesterol and suppressed by bile acids.
- An alternative pathway involves the cyp7B gene, which is expressed in the brain as well as other tissues.
- cholesterol catabolism plays a central role in cholesterol homeostasis.
- treatment of laboratory animals with cholestid or cholestyramine, two bile acid-binding resins decreases serum cholesterol levels.
- overexpression of the cyp7 gene in hamsters reduces both total cholesterol levels and LDL cholesterol levels.
- cholesterol 7 ⁇ -hydrolase is a potential therapeutic target for the identification of cholesterol reducing compounds and, thus, understanding the mechanism by which expression of the cyp7 genes are regulated is of particular importance.
- Nuclear receptors form a large family of ligand-activated transcription factors that modify the expression of target genes by binding to specific cis-acting sequences (Laudet et al. (1992) EMBO J. 11: 1003-1013; Lopes da Silva et al. (1995) Trends Neurosci. 18: 542-548; Mangelsdorf et al. (1995) Cell 83: 835-839; Mangelsdorf and Evans (1995) Cell 83: 841-850).
- Nuclear receptors include those that remain sequestered in the cytoplasm in the absence of their cognate ligands (e.g., steroid hormone receptors). Upon binding of the ligand, the steroid hormone receptors are translocated to the nucleus where they bind to hormone response elements, typically as homodimers.
- nuclear receptors Most of the nuclear receptors, conversely, are not sequestered in the cytoplasm in the absence of their ligands but rather remain in the nucleus. These receptors, which include the thyroid hormone, retinoid, fatty acid, and eicosanoid receptors, typically bind to their cognate response elements as heterodimers with a 9-cis-retinoic acid receptor (RXR). Often, binding of a nuclear receptor to a response element occurs in the absence of the cognate ligand.
- RXR 9-cis-retinoic acid receptor
- FXR famesoid X receptor
- RIP 14 also known as “RIP 14” and “NR1H4”
- NR1H4 famesoid X receptor
- the present invention is based in part on the discovery that the orphan nuclear receptor FXR (famesoid X receptor) is involved in the suppression of the human cyp7 genes. More particularly, it has been discovered that FXR functions as a bile acid receptor/sensor that mediates cyp7 expression in a bile-acid dependent manner.
- the present invention provides a method for increasing cholesterol metabolism in a cell by contacting the cell with a compound that modulates the binding of an FXR to a ligand for FXR.
- the ligand is a bile acid.
- the compound modulates the binding of the FXR to an RXR or other coactivator or corepressor.
- the invention provides methods for prescreening to identify a candidate therapeutic compound suitable for testing for ability to modulate cholesterol metabolism in a cell. These methods involve:
- reaction mixture that comprises:
- determining whether the amount of binding of the FXR ligand binding domain to the ligand for FXR is increased or decreased in the presence of the test compound compared to the amount of binding in the absence of the test compound.
- a test compound that causes an increase or decrease in binding is a candidate therapeutic agent for modulation of cholesterol metabolism.
- the methods further involve administering the candidate therapeutic agent to a cell to determine whether the candidate therapeutic agent modulates cholesterol metabolism in the cell.
- the invention also provides methods for screening to identify a compound that modulates cholesterol metabolism in a cell using a gene expression assay. For example, these methods can involve contacting a cell with a test compound, wherein said cell includes:
- a reporter gene construct which comprises a response element to which said DNA binding domain can bind, wherein said response element is operably linked to a promoter that is operative in the cell and said promoter is operably linked to a reporter gene.
- the reporter gene By determining whether the reporter gene is expressed at a higher or lower level in the presence of said test compound compared to said reporter gene expression level in the absence of said test compound, one can identify a test compound that can modulate cholesterol metabolism in a cell.
- the cells used in the methods of the invention are typically mammalian cells. In a presently preferred embodiment, the cell is in a mammal and, in particular, in a human.
- test compounds are, in some embodiments, a compound that binds to FXR or to the ligand for FXR, and thus inhibits binding of the ligand to the FXR.
- the compound can be an antibody that binds to FXR, or an organic molecule that interferes with the interaction.
- the binding of the compound can also modulate the binding of a transcription complex that comprises FXR to a response element.
- Response elements of particular interest include those that are derived from a region upstream of a cyp7 gene.
- the present invention provides a method for reducing cholesterol levels in a mammal. These methods involve administering to said mammal a compound that modulates the binding of an FXR to an FXR response element.
- the mammal is a human.
- the invention also provides assays for identifying ligands for FXR, and response elements that are bound by FXR or by a transcription complex that includes FXR.
- FIGS. 1A and 1B illustrate that the bile acid CDCA specifically transactivates FXR.
- FIG. 1A illustrates that a GAL4 DNA binding domain fused to an FXR ligand binding domain is activated by CDCA, while ligand binding domains of other nuclear receptors fused to the GAL4 DBD are not activated by CDCA.
- FIG. 1B illustrates that CDCA-mediated transactivation of FXR is dose-dependent.
- FIGS. 2A and 2B illustrate that FXR suppresses cyp7 expression.
- FIG. 2A illustrates that CDCA-mediated suppression of cyp7 is specific to FXR.
- FIG. 2B illustrates a dose-response profile of CDCA-mediated suppression of cyp7 expression by FXR.
- FIGS. 3A, 3B and 3 C illustrate that FXR suppression is specific to cyp7.
- FIG. 3A illustrates that FXR does not suppress expression of the low density lipoprotein (LDL) receptor.
- FIG. 3B illustrates that titrating away FXR causes a loss of cyp7 suppression.
- FIG. 3C illustrates that FXR mutants do not suppress cyp7 expression.
- LDL low density lipoprotein
- FIGS. 4A and 4B, 4 C and 4 D illustrate the effect of different bile acids on FXR activity.
- FIG. 4A illustrates a western blot analysis of cyp7 expression, as well as a quantitative RT-PCR analysis of cyp7 mRNA in HepG2 cells.
- FIG. 4B illustrates that FXR interacts with the co-activator SRC-1 in a mammalian two-hybrid assay.
- FIG. 4C shows the effect of different bile acids on FXR-mediated transactivation.
- FIG. 4D shows the effect of the bile acids on FXR-mediated suppression of cyp7 expression.
- FIG. 5A illustrates the results of a peptide sensor assay using a GST-FXR fusion protein.
- FIG. 5B shows the results of an analysis in which FRET was used to monitor the effect of bile acids and derivatives on FXR/SRC-1 interaction.
- FIG. 5C shows the results of a sensor peptide study in which ELISA was used to detect binding of the sensor peptide to the FXR LBD in the presence of increasing concentrations of different bile acids and derivatives.
- isolated refers to material that is substantially or essentially free from components which normally accompany the enzyme as found in its native state.
- the polypeptides of the invention do not include materials normally associated with their in situ environment.
- isolated proteins of the invention are at least about 80% pure, usually at least about 90%, and preferably at least about 95% pure as measured by band intensity on a silver stained gel or other method for determining purity. Protein purity or homogeneity can be indicated by a number of means well known in the art, such as polyacrylamide gel electrophoresis of a protein sample, followed by visualization upon staining. For certain purposes high resolution will be needed and HPLC or a similar means for purification utilized.
- recombinant when used with reference to a cell, or nucleic acid, or vector, indicates that the cell, or nucleic acid, or vector, has been modified by the introduction of a heterologous nucleic acid or the alteration of a native nucleic acid, or that the cell is derived from a cell so modified.
- recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all.
- nucleic acids or polypeptide sequences refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual alignment and inspection.
- substantially identical in the context of two nucleic acids or polypeptides, refers to two or more sequences or subsequences that have at least 75%, preferably 85%, most preferably 90-95% nucleotide or amino acid residue identity, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection.
- the substantial identity exists over a region of the sequences that is at least about 50 residues in length, more preferably over a region of at least about 100 residues, and most preferably the sequences are substantially identical over at least about 150 residues.
- the sequences are substantially identical over the entire length of the coding regions and/or untranslated regions.
- a further indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the polypeptide encoded by the second nucleic acid, as described below.
- a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions.
- Another indication that two nucleic acid sequences are substantially identical is that the two molecules hybridize to each other under stringent conditions, as described below.
- Bind(s) substantially refers to complementary hybridization between a probe nucleic acid and a target nucleic acid and embraces minor mismatches that can be accommodated by reducing the stringency of the hybridization media to achieve the desired detection of the target polynucleotide sequence.
- hybridizing specifically to refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent conditions when that sequence is present in a complex mixture (e.g., total cellular) DNA or RNA.
- stringent conditions refers to conditions under which a probe will hybridize to its target subsequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. Generally, stringent conditions are selected to be about 5° C. lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH.
- the Tm is the temperature (under defined ionic strength, pH, and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. (As the target sequences are generally present in excess, at Tm, 50% of the probes are occupied at equilibrium).
- stringent conditions will be those in which the salt concentration is less than about 1.0 M Na + , typically about 0.01 to 1.0 M Na + concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30° C. for short probes (e.g., 10 to 50 nucleotides) and at least about 60° C. for long probes (e.g., greater than 50 nucleotides).
- Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.
- the specified antibodies or other ligand bind to a particular protein and do not bind in a significant amount to other proteins present in the sample.
- Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular protein.
- antibodies raised to the FXR polypeptides (or subsequences thereof) or to the polypeptides partially encoded by the FXR polynucleotide sequences can be selected to obtain antibodies specifically immunoreactive with the full length proteins and not with other proteins, except perhaps to polymorphic variants.
- a variety of immunoassay formats can be used to select antibodies and other molecules that specifically bind to a particular protein such as FXR.
- solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically immunoreactive with a protein.
- a specific or selective reaction will be at least twice background signal or noise and more typically more than 10 to 100 times background.
- the present invention pertains to the discovery that ligands for the formerly orphan receptor FXR include bile acids, and that the binding of a bile acid to FXR results in suppression of cholesterol catabolism. Accordingly, the invention provides methods for modulating (i.e., increasing or decreasing) cholesterol levels in a cell by contacting the cell with a compound that modulates the binding of FXR to ligand for FXR.
- a compound By decreasing binding of the FXR to an FXR ligand, for example, a compound can reduce the suppression of a gene such as cyp7 (i.e., increase the expression) which encodes an enzyme that is a key enzyme in cholesterol metabolism.
- Also provided by the invention are methods for increasing or decreasing cholesterol levels in a mammal, including humans by administering to the mammal a compound that modulates the binding of FXR to an FXR ligand.
- the invention provides methods for identifying compounds that can modulate cholesterol metabolism by, for example, altering the ability of FXR to bind to FXR ligands.
- the invention also provides screening assays for identifying compounds that can modulate cholesterol metabolism. These compounds can function by, for example, altering the interaction between FXR and FXR ligands (e.g., bile acids, corepressors and/or coactivators) and/or between FXR and its response elements. Of particular interest is the modulation of cyp7 gene expression, which is inhibited by binding of FXR to the upstream region of the gene. Thus, a compound that inhibits the cis-repressing activity of FXR can increase the expression of cyp7, thus increasing degradation of cholesterol. Compounds that are identified using the screening methods of the invention find use in studies of gene regulation, and also find therapeutic use in situations in which it is desirable to increase or decrease cholesterol metabolism. Other uses will also be apparent those of ordinary skill in the art.
- FXR and FXR ligands e.g., bile acids, corepressors and/or coactivators
- the assays of the invention are amenable to screening of large chemical libraries by automating the assay steps and providing compounds from any convenient source to assays, which are typically run in parallel (e.g., in microtiter formats on microtiter plates in robotic assays).
- any chemical compound can be used as a potential FXR activity modulator in the assays of the invention.
- compounds that can be dissolved in aqueous or organic (especially DMSO-based) solutions are used. It will be appreciated that there are many suppliers of chemical compounds, including Sigma (St. Louis, Mo.), Aldrich (St. Louis, Mo.), Sigma-Aldrich (St. Louis, Mo.), Fluka Chemika-Biochemica Analytika (Buchs Switzerland) and the like.
- high throughput screening methods involve providing a combinatorial library containing a large number of potential therapeutic compounds (potential modulator compounds). Such “combinatorial chemical libraries” are then screened in one or more assays, as described herein, to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity (e.g., inhibit the interaction between FXR and an FXR ligand). The compounds thus identified can serve as conventional “lead compounds” or “candidate therapeutic agents,” or can themselves be used as potential or actual therapeutics.
- a combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis, by combining a number of chemical “building blocks” such as reagents.
- a linear combinatorial chemical library such as a polypeptide library is formed by combining a set of chemical building blocks (amino acids) in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks.
- combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Pat. No. 5,010,175, Furka, Int. J. Pept. Prot. Res. 37:487-493 (1991) and Houghton et al., Nature 354:84-88 (1991)).
- chemistries for generating chemical diversity libraries can also be used. Such chemistries include, but are not limited to: peptoids (PCT Publication No.
- nucleic acid libraries see, Ausubel, Berger and Sambrook, all supra
- peptide nucleic acid libraries see, e.g., U.S. Pat. No. 5,539,083
- antibody libraries see, e.g., Vauglui et al., Nature Biotechnology, 14(3):309-314 (1996) and PCT/US96/10287)
- carbohydrate libraries see, e.g., Liang et al., Science, 274:1520-1522 (1996) and U.S. Pat. No.
- the invention provides both biochemical and cell-based assays for identifying compounds that can modulate FXR-mediated regulation of cholesterol metabolism. Often, an initial assay is performed in vitro to identify compounds that are potential candidate therapeutic agents, after which such compounds are then tested in vivo by, for example, administering the compound to a test animal to determine whether cholesterol levels are affected.
- the invention provides methods for identifying compounds that are suitable for further testing as candidate therapeutic agents for treatment of hypercholesteremia and other conditions that are associated with cholesterol synthesis and metabolism.
- Compounds that exhibit the desired activity in the in vitro assays can be used for further studies of the regulation of pathways involved in cholesterol hemostasis, or can be subjected for further testing to identify those that are suitable for use to treat hypercholesterolemia or other conditions involving cholesterol metabolism.
- One type of assay that can be used is a direct binding assay, which measures the amount of a compound that can bind to an FXR polypeptide or to a polypeptide that has an FXR ligand binding domain.
- These assays can be carried out using labeled candidate therapeutic agents which are then incubated with a polypeptide that has an FXR ligand binding domain (e.g., a full-length FXR polypeptide or a fusion protein).
- Labels include radioisotopes, immunochemicals, fluorophores, and the like.
- the affinity of the labeled candidate therapeutic agent for an FXR polypeptide can be calculated using standard ligand binding methods.
- Another type of assay that can be used to pre-screen candidate therapeutic agents involves testing the ability of a test compound to modulate binding of FXR to a ligand for FXR. These can be conducted, for example, as a direct binding assay with a labeled FXR ligand in the presence of a candidate therapeutic agent.
- the assays involve placing the test compound into an assay mixture that includes at least a ligand binding domain of an FXR polypeptide and a ligand for FXR. The effect on binding of the FXR ligand to FXR is determined.
- a test compound that decreases the amount of labeled FXR ligand that is bound to an FXR polypeptide or a polypeptide that has an FXR ligand binding domain, is of interest for future screening for its ability to modulate cholesterol levels in vivo.
- Ligands that are suitable for use in the assays of the invention include, but are not limited to, bile acids and related compounds such as CDCA (chenodeoxycholic acid), GCDCA (glycochenodeoxycholic acid), TCDCA (taurochenodeoxycholic acid), GCA (glycocholic acid), TCA (taurocholic acid), DCA (deoxycholic acid), LCA (lithocholic acid), DHCA (dehydrocholic acid), UDCA (ursodeoxycholic acid) and CA (cholic acid).
- the bile acid is CDCA. Additional bile acids and other ligands are described in, for example, Makishima et al. (1999) Science 284: 1362-1365.
- the assays can also employ coactivators and corepressors with which FXR interacts. Methods of identifying FXR ligands are described below.
- an assay such as the fluorescence polarization assay or the fluorescence resonance energy transfer assay is employed to identify candidate therapeutic agents. These assays do not require the separation of bound and free labeled test compound.
- Fluorescence polarization (FP) or fluorescence anisotropy is a useful tool for the study of molecular interactions (see, e.g. http://www.panvera.com/tech/appguide/fpintro.html, Nov. 4, 1999).
- FP Fluorescence polarization
- fluorescence anisotropy is a useful tool for the study of molecular interactions (see, e.g. http://www.panvera.com/tech/appguide/fpintro.html, Nov. 4, 1999).
- Fluorescence polarization is calculated as shown in the following Formula I:
- Int ⁇ is the intensity of the emission parallel to the excitation plane. Int ⁇ is the intensity of the emission perpendicular to the excitation plane.
- a small fluoreseently labeled molecule when free in solution, can emit depolarized light when excited with the proper wavelength of light. If, however, the molecule (e.g., a ligand) binds to a second molecule (e.g., a receptor) the fluorescently labeled molecule is more constrained so the light emitted is more polarized and the fluorescence polarization (FP) value is higher. Thus, a higher FP value indicates that the fluorescently labeled molecule is able to bind to the second molecule.
- a competition assay also can be performed using FP. If an unlabeled molecule is present in the solution, then it will compete for binding to the second molecule, e.g., the antibody and the FP value will be decreased. Thus, FP can be used in competitive assays.
- test compounds can be fluorescently labeled with a fluorophore that is active in a FP assay.
- fluorescein Panvera, publications Lit. # L0057 and L0059
- small fluorescent compound for example, N-terminal amines of proteins, peptide, or peptide analogs can be labeled with fluorescein (Panvera, publications Lit. # L0057 and L0059) or a small fluorescent compound.
- a fluorescein-C 6 -succinimidyl ester can be conjugated to peptides or proteins.
- the fluorescein labeled peptide/protein can then be purified from the unreacted fluorescein-C6-succinimidyl ester using thin-layer chromatography or gel filtration chromatography. If the labeled test compound can bind to a polypeptide that has an FXR ligand binding domain, the level of polarization is increased.
- the FP assay also can be used to assay the ability of a fluorescently labeled FXR ligand to bind to an FXR polypeptide.
- a test compound can be screened for its ability to decrease the FP of a fluorescently labeled known FXR ligand complexed with an FXR polypeptide or a polypeptide comprising an FXR ligand binding domain.
- a known FXR ligand is labeled with a fluorescent moiety.
- a test compound that decreases the FP value of the fluorescently labeled FXR ligand and FXR is displacing or inhibiting the ability of the fluorescently labeled FXR ligand to bind to the ligand binding domain of FXR.
- FRET fluorescence resonance energy transfer
- FRET FRET
- fluorescent labels dyes, enzymatic labels, and antibody labels are all appropriate.
- preferred interactive fluorescent label pairs include terbium chelate and TRITC (tetrarhodamine isothiocyanate), europium cryptate and allophycocyanin and many others known to one of skill.
- two colorimetric labels can result in combinations that yield a third color, e.g., a blue emission in proximity to a yellow emission produces an observed green emission.
- Fluorescence quenching is a bimolecular process that reduces the fluorescence quantum yield, typically without changing the fluorescence emission spectrum. Quenching can result from transient excited interactions, (collisional quenching) or, e.g., from the formation of nonfluorescent ground state species. Self-quenching is the quenching of one fluorophore by another; it tends to occur when high concentrations, labeling densities, or proximity of labels occurs.
- excited fluorophores interact to form excimers, which are excited state dimers that exhibit altered emission spectra (e.g., phospholipid analogs with pyrene sn-2 acyl chains); See Haugland (1996) Handbook of Fluorescent Probes and Research Chemicals , published by Molecular Probes, Inc., Eugene, Oreg.
- the Forster radius (R o ) is the distance between fluorescent pairs at which energy transfer is 50% efficient (i.e., at which 50% of excited donors are deactivated by FRET).
- nitroxide-labeled molecules such as fatty acids.
- Spin labels such as nitroxides are also useful in the liquid phase assays of the invention.
- Test compounds and a polypeptide that includes an FXR ligand binding domain can be labeled with FRET pairs. If the test compound can directly interact with the FXR ligand binding domain, fluorescence resonance energy transfer can take place and the affinity can be measured. Alternatively, a known FXR ligand can be labeled with an appropriate FRET label and incubated with an FRET fluorophore labeled polypeptide that includes an FXR ligand binding domain. Fluorescence resonance energy transfer can take place between the labeled FXR ligand and the labeled FXR ligand binding domain. If a test compound were incubated with the two labeled components, the amount of FRET would be lowered if the test compound can inhibit or displace the binding of the labeled FXR ligand to the FXR ligand binding domain.
- peptide sensors Additional methods for assaying the ability of test compounds to modulate FXR interactions with its ligands employ peptide sensors. These assays can be adapted from those described in WO 99/27365. Briefly, these assays use a peptide sensor to which is attached a detectable label. The peptides are based on corepressor or coactivator protein motif sequences, either naturally occurring or derived from mutational analysis. The peptide sensors are derived from corepressors or coactivators that interact with FXR (e.g., a p160 coactivator, RXR, CPF, and others that are identified as described herein).
- FXR e.g., a p160 coactivator, RXR, CPF, and others that are identified as described herein).
- the peptides can be obtained through randomizing residues and selecting for binding to the FXR receptor polypeptide. Panels of predetermined or randomized candidate sensors can be screened for receptor binding.
- FXR peptide sensor assays an example of a suitable peptide sensor is derived from the receptor-interacting domain of the coactivator SRC-1. This domain has been mapped to a short motif with the amino acid sequence LXXLL, where L is leucine and X is any amino acid. Fragments of SRC-1 or short synthetic peptides containing one LXXLL motif or more bind nuclear receptors in a ligand-dependent manner (Darimont et al. (1998) Genes Dev. 12: 3343; McInerney et al. (1998) Genes Dev. 12: 3357).
- the sensor peptides are labeled with a detectable label.
- the detectable labels can be primary labels (where the label comprises an element that is detected directly or that produces a directly detectable element) or secondary labels (where the detected label binds to a primary label, as is common in immunological labeling).
- An introduction to labels, labeling procedures and detection of labels is found in Polak and Van Noorden (1997) Introduction to Immunocytochemistry, 2nd ed., Springer Verlag, N.Y. and in Haugland (1996) Handbook of Fluorescent Probes and Research Chemicals , a combined handbook and catalogue published by Molecular Probes, Inc., Eugene, Oreg.
- Primary and secondary labels can include undetected elements as well as detected elements.
- Useful primary and secondary labels in the present invention can include spectral labels such as fluorescent dyes (e.g., fluorescein and derivatives such as fluorescein isothiocyanate (FITC) and Oregon GreenTM, rhodamine and derivatives (e.g., Texas red, tetrarhodimine isothiocynate (TRITC), etc.), digoxigenin, biotin, phycoerythrin, AMCA, CyDyesTM, and the like), radiolabels (e.g., 3H, 125I, 35S, 14C, 32P, 33P, etc.), enzymes (e.g., horse radish peroxidase, alkaline phosphatase etc.), spectral colorimetric labels such as colloidal gold or colored glass or plastic (e.g., polystyrene, polypropylene, latex, etc.) beads.
- fluorescent dyes e.g., fluorescein and derivatives such as fluoresc
- the label may be coupled directly or indirectly to a component of the detection assay (e.g., the detection reagent) according to methods well known in the art.
- a component of the detection assay e.g., the detection reagent
- the detectable label is a fluorescent label, in which case fluorescence polarization detection provides a sensitive and efficient means of detecting whether the peptide sensor is bound to the FXR receptor polypeptide. See, e.g., Schindler et al. (1995) Immunity 2: 689-697).
- the sensor peptide and the FXR polypeptide are incubated under conditions that are suitable for sensor binding to the receptor polypeptide.
- a candidate modulator of FXR binding to a corepressor, coactivator or other ligand is included in the reaction mixture. If a candidate modulator increases or decreases binding of the sensor peptide to the FXR polypeptide, the candidate modulator is a potential lead compound for blocking the FXR-mediated effect on transcription.
- the present invention also provides cell-based methods for screening to identify compounds that are suitable for use as cholesterol level-mediating therapeutic agents, or that are suitable to further screening compounds that exhibit activity in the polypeptide-based assays described above. These methods provide an assay to determine whether expression of a gene involved in cholesterol hemostasis is affected by administration of the test compound.
- these screening methods of the invention use a cell that contains a polypeptide that has a ligand binding domain (LBD) which is at least substantially identical to that of an FXR.
- the polypeptide typically will also include a DNA binding domain (DBD).
- the DBD can be substantially identical to that of an FXR (i.e., a full-length FXR is used), or to that of a receptor other than FXR for which the response element is known (e.g., GAL4, nuclear hormone receptors, and the like). Examples of suitable chimeric polypeptides are described in more detail below.
- the chimeric receptor polypeptide is introduced into the cell by expression of a polynucleotide that encodes the receptor polypeptide.
- a polynucleotide that encodes the receptor polypeptide can be introduced into the cell that is to be used in the assay. Suitable FXR polypeptides and chimeric receptors are described below.
- the cells will also contain a response element that can be bound by the DNA binding domain.
- Response elements including glucocorticoid response elements (GRE) and estrogen response elements (ERE), are described in, for example, Jantzen et al. (1987) Cell 49: 29; Martinez et al. (1987) EMBO J. 6: 3719 and Burch et al. (1988) Mol. Cell. Biol. 8: 1123.
- GRE glucocorticoid response elements
- ERP estrogen response elements
- Many other response elements are known; a commonly used response element is the GAL4 upstream activating sequence (UAS G ) (Keegan et al. (1986) Science 14: 699-704), which is responsive to binding by chimeric receptors that include the GAL4 DNA binding domain.
- UAS G GAL4 upstream activating sequence
- the response element that is bound by the DNA binding domain used in the chimeric polypeptide is generally used in a reporter gene construct.
- the response element is operably linked to a promoter that is active in the cell.
- the promoter is operably linked to a reporter gene that, when expressed, produces a readily detectable product.
- the response element/reporter gene construct is conveniently introduced into cells as part of a “reporter plasmid.”
- Suitable promoters include those described above.
- the promoter is operably linked to a reporter gene that, when expressed, produces a readily detectable product.
- reporter gene plasmid systems such as the chloramphenicol acetyltransferase (CAT) and ⁇ -galactosidase (e.g., bacterial lacZ gene) reporter systems, the firefly luciferase gene (See, e.g., Cara et al. (1996) J. Biol. Chem., 271: 5393-5397), the green fluorescence protein (see, e.g., Chalfie et al. (1994) Science 263:802) and many others.
- CAT chloramphenicol acetyltransferase
- ⁇ -galactosidase e.g., bacterial lacZ gene
- the firefly luciferase gene See, e.g., Cara et al. (1996) J. Biol. Chem
- reporter plasmids examples include bovine serum, bovine serum, and bovine serum.
- Selectable markers which facilitate cloning of the vectors of the invention are optionally included. Sambrook and Ausubel, both supra, provide an overview of selectable markers.
- the reporter plasmid and an expression plasmid that directs expression of the chimeric receptor are introduced into a suitable host cell.
- Standard transfection methods can be used to introduce the vectors into the host cells.
- preferred transfection methods include, for example, calcium phosphate precipitation (Chen and Okayama (1988) BioTechniques 6: 632), DEAE-dextran, and cationic lipid-mediated transfection (e.g., Lipofectin) (see, e.g., Ausubel, supra.).
- the host cell, prior to introduction of the expression plasmid should not contain an FXR receptor. See, e.g., U.S. Pat. No. 5,071,773 for suitable host cells for use in the assays.
- the assay methods involve contacting test cells that contain the reporter plasmid, the native or chimeric FXR polypeptide, and a ligand (e.g., bile acid) with the test compound.
- a ligand e.g., bile acid
- an RXR polypeptide and/or other coactivators and corepressors which mediate the effect of FXR are also present in the test cells.
- a cell that contains a reporter gene construct and the chimeric peptide can be grown in the presence and absence of putative modulatory compounds.
- the observed effect on reporter gene expression can depend on the particular assay system used. For example, when an FXR polypeptide that includes the FXR DBD, AF-2 domain, and LBD is used, cells grown in the absence of the FXR ligand will exhibit a level of reporter gene expression that is above the level observed in the absence of the ligand. Conversely, when a GAL4 DBD is used, binding of the ligand to the fusion polypeptide will result in increased expression the reporter gene to which is linked the GAL4 response element. Therefore, reporter gene expression is increased when cells are grown in the presence of a ligand for the FXR.
- the assays of the invention typically employ an FXR polypeptide.
- the FXR polypeptide can be a full-length FXR, or can include one or more domains of FXR.
- one or more FXR domains e.g., a DNA binding domain (DBD) or a ligand binding domain (LBD)
- DBD DNA binding domain
- LBD ligand binding domain
- some assay formats use a fusion protein that includes an FXR LBD fused to a DBD of another receptor.
- the FXR polypeptides and fusion polypeptides used in the assays of the invention can be made by methods known to those of skill in the art.
- the FXR proteins or subsequences thereof can be synthesized using recombinant DNA methodology. Generally this involves creating a DNA sequence that encodes the polypeptide, modified as desired, placing the DNA in an expression cassette under the control of a particular promoter, expressing the protein in a host, isolating the expressed protein and, if required, renaturing the protein.
- FXR polypeptides and polynucleotides that encode FXR polypeptides, are known to those of skill in the art.
- cDNA sequences of FXR polypeptides from human U68233
- Branchiostoma lanceolatum U93409
- Danio rerio zebrafish
- rat U18374
- GenBank GenBank
- FXR-encoding nucleic acids can be isolated by cloning or amplification by in vitro methods, such as the polymerase chain reaction (PCR), the ligase chain reaction (LCR), the transcription-based amplification system (TAS), the self-sustained sequence replication system (SSR).
- PCR polymerase chain reaction
- LCR ligase chain reaction
- TAS transcription-based amplification system
- SSR self-sustained sequence replication system
- FXR cDNAs can be isolated by routine cloning methods.
- GenBank for example, can be used to provide probes that specifically hybridize to a FXR gene in a genomic DNA sample, to an FXR mRNA in a total RNA sample, or to a FXR cDNA in a cDNA library (e.g., in a Southern or Northern blot).
- a FXR cDNA library e.g., in a Southern or Northern blot.
- the FXR nucleic acids can be isolated by amplification methods such as polymerase chain reaction (PCR).
- PCR polymerase chain reaction
- a polynucleotide that encodes an FXR polypeptide or fusion protein can be operably linked to appropriate expression control sequences for a particular host cell in which the polypeptide is to be expressed.
- appropriate control sequences include a promoter such as the T7, trp, or lambda promoters, a ribosome binding site and preferably a transcription termination signal.
- the control sequences typically include a promoter which optionally includes an enhancer derived from immunoglobulin genes, SV40, cytomegalovirus, etc., and a polyadenylation sequence, and may include splice donor and acceptor sequences.
- yeast convenient promoters include GAL1,10 (Johnson and Davies (1984) Mol. Cell. Biol. 4:1440-1448) ADH2 (Russell et al. (1983) J. Biol. Chem. 258:2674-2682), PHO5 ( EMBO J. (1982) 6:675-680), and MF ⁇ 1 (Herskowitz and Oshima (1982) in The Molecular Biology of the Yeast Saccharomyces (eds. Strathem, Jones, and Broach) Cold Spring Harbor Lab., Cold Spring Harbor, N.Y., pp. 181-209).
- Expression cassettes are typically introduced into a vector which facilitates entry into a host cell, and maintenance of the expression cassette in the host cell.
- Vectors that include a polynucleotide that encodes an FXR polypeptide are provided by the invention. Such vectors often include an expression cassette that can drive expression of the FXR polypeptide.
- To easily obtain a vector of the invention one can clone a polynucleotide that encodes the FXR polypeptide into a commercially or commonly available vector.
- a variety of common vectors suitable for this purpose are well known in the art. For cloning in bacteria, common vectors include pBR322 derived vectors such as pBLUESCRIPTTM, and k-phage derived vectors.
- vectors include Yeast Integrating plasmids (e.g., YIp5) and Yeast Replicating plasmids (the YRp series plasmids) and pGPD-2.
- YIp5 Yeast Integrating plasmids
- YRp series plasmids the YRp series plasmids
- pGPD-2 pGPD-2
- a multicopy plasmid with selective markers such as Leu-2, URA-3, Trp-1, and His-3 is also commonly used.
- a number of yeast expression plasmids such as YEp6, YEp13, YEp4 can be used as expression vectors.
- the above-mentioned plasmids have been fully described in the literature (Botstein et al. (1979) Gene 8:17-24; Broach et al. (1979) Gene, 8:121-133).
- yeast expression plasmids see, e.g., Parents, B., YEAST (1985), and Ausubel, Sambrook, and Berger, all supra).
- Expression in mammalian cells can be achieved using a variety of commonly available plasmids!, including pSV2, pBC12BI, and p91023, as well as lytic virus vectors (e.g., vaccinia virus, adenovirus, and baculovirus), episomal virus vectors (e.g., bovine papillomavirus), and retroviral vectors (e.g., murine retroviruses).
- lytic virus vectors e.g., vaccinia virus, adenovirus, and baculovirus
- episomal virus vectors e.g., bovine papillomavirus
- retroviral vectors e.g., murine retroviruses.
- FXR polypeptides and fusion polypeptides that include at least one FXR domain can be expressed in a variety of host cells, including E. coli , other bacterial hosts, yeasts, filamentous fungi, and various higher eukaryotic cells such as the COS, CHO and HeLa cells lines and myeloma cell lines. Techniques for gene expression in microorganisms are described in, for example, Smith, Gene Expression in Recombinant Microorganisms ( Bioprocess Technology , Vol. 22), Marcel Dekker, 1994.
- bacteria examples include, but are not limited to, Escherichia, Enterobacter, Azotobacter, Erwinia, Bacillus, Pseudomonas, Klebsielia, Proteus, Salmonella, Serratia, Shigella, Rhizobia, Vitreoscilla, and Paracoccus.
- Filamentous fungi that are useful as expression hosts include, for example, the following genera: Aspergillus, Trichoderma, Neurospora, Penicillium, Cephalosporium, Achlya, Podospora, Mucor, Cochliobolus, and Pyricularia. See, e.g., U.S. Pat. No.
- nucleic acids that encode the polypeptides of the invention can be transferred into the chosen host cell by well-known methods such as calcium chloride transformation for E. coli and calcium phosphate treatment or electroporation for mammalian cells.
- Cells transformed by the plasmids can be selected by resistance to antibiotics conferred by genes contained on the plasmids, such as the amp, gpt, neo and hyg genes, among others.
- Techniques for transforming fungi are well known in the literature and have been described, for instance, by Beggs et al. ((1978) Proc. Nat'l. Acad. Sci. USA 75: 1929-1933), Yelton et al. ((1984) Proc. Natl. Acad.
- the FXR polypeptides and/or fusion proteins can be purified, either partially or substantially to homogeneity, according to standard procedures of the art, such as, for example, ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis and the like (see, generally, R. Scopes, Protein Purification , Springer-Verlag, N.Y. (1982), Deutscher, Methods in Enzymology Vol. 182: Guide to Protein Purification., Academic Press, Inc. N.Y. (1990)).
- the polypeptides may then be used (e.g., in screening assays for modulators for gene expression or as immunogens for antibody production).
- the FXR polypeptides and/or fusion proteins may possess a conformation substantially different than the native conformations of the constituent polypeptides. In this case, it may be necessary to denature and reduce the polypeptide and then to cause the polypeptide to re-fold into the preferred conformation. Methods of reducing and denaturing proteins and inducing re-folding are well known to those of skill in the art (See, Debinski et al. (1993) J. Biol. Chem., 268: 14065-14070; Kreitman and Pastan (1993) Bioconjug.
- FXR polypeptides without diminishing their biological activity. Such modifications can be made to facilitate the cloning, expression, or incorporation of the polypeptide into a fusion protein. Such modifications are well known to those of skill in the art and include, for example, a methionine added at the amino terminus to provide an initiation site, or additional amino acids (e.g., poly His) placed on either terminus to create conveniently located restriction sites or termination codons or purification sequences.
- modifications are well known to those of skill in the art and include, for example, a methionine added at the amino terminus to provide an initiation site, or additional amino acids (e.g., poly His) placed on either terminus to create conveniently located restriction sites or termination codons or purification sequences.
- the assays of the invention sometimes employ a chimeric FXR polypeptide that has at least a ligand binding domain and a DNA binding domain. At least one of the ligand binding domain and the DNA binding domain of the chimeric receptors of the invention is substantially identical to the corresponding domain of an FXR.
- These chimeric receptors are useful for many purposes. For example, one can use the chimeric receptors to identify additional ligands for the FXR and to identify response elements that are responsive to FXR.
- the chimeric receptors are also useful in screening assays for identifying compounds that can modulate interactions between FXR and its ligands and/or response elements.
- the chimeric receptors used in the assays of the invention include those having a ligand binding domain that is at least substantially identical to a ligand binding domain of an FXR, as well as those that have a DNA binding domain that is not substantially identical to a DNA binding domain of an FXR.
- the DNA binding domain binding domain can be about 90% or less identical to that of an FXR, more preferably about 75% or less, and most preferably about 60% or less identical.
- the DNA binding domain is derived from a receptor other than a FXR.
- the DNA binding domain is at least substantially identical to a DNA binding domain from a nuclear hormone receptor or a steroid hormone receptor.
- DNA binding domains derived from steroid, thyroid, and retinoid hormone receptor are suitable for use in the chimeric receptors of the invention.
- the DNA binding domains of receptors for steroid, thyroid, and retinoid hormones typically include two zinc finger units (Rhodes and Klug (February 1993) Scientific American , pp. 56-65).
- the DNA binding domains of these receptors are generally cysteine-rich regions of about 65 amino acids that fold into two cysteine-rich “C4” type zinc fingers.
- Examples of receptors from which one can derive DNA binding domains that are suitable for use in the chimeric receptors of the invention include, for example, androgen receptors, estrogen receptors, glucocorticoid receptors, mineralcorticoid receptors, progesterone receptors, retinoic acid receptors (including ⁇ , ⁇ (hap), and ⁇ ), thyroid hormone receptors (including ⁇ and ⁇ ), the gene product of the avian erythroblastosis virus oncogene v-erbA (which is derived from a cellular thyroid hormone receptor), vitamin D3 receptor, Drosophila ecdysone receptor (EcR), COUP transcription factor (also known as ear3) and its Drosophila homolog 7UP (svp), hepatocyte nuclear factor 4 (HNF-4), Ad4BP, apolipoprotein AI regulatory protein-1 (ARP-1), peroxisome proliferator activated receptor (PPAR), Drosophila protein knirps (k
- the chimeric receptors include a DNA binding domain from a DNA-binding polypeptide other than a nuclear receptor.
- a DNA binding domain from a DNA-binding polypeptide other than a nuclear receptor For example, chimeric receptors that have the DNA binding domain of GAL4, which is a positive regulatory protein of yeast (Giniger et al. (1985) Cell 40: 767-774; Sadowski et al. (1992) Gene 118: 137-141) linked to a ligand binding domain of an FXR polypeptide are provided.
- GAL4 DNA binding domain-containing fusion proteins can be readily expressed by cloning a coding sequence for an FXR ligand binding domain into a commercially available expression vector that includes a GAL4 DNA binding domain coding sequence under the control of a promoter (e.g., pAS2-1 (CLONTECH Laboratories, Inc.).
- a promoter e.g., pAS2-1 (CLONTECH Laboratories, Inc.).
- Another example of a well-characterized DNA binding domain for which expression vectors are commercially available is that of LexA (pLexA, CLONTECH).
- the chimeric receptors can also include a nuclear localization sequence associated with the DNA binding domain (see, e.g., Silver et al. (1984) Proc. Nat'l. Acad. Sci. USA 81: 5951-5955 for a GAL4 nuclear localization sequence).
- the chimeric receptors can use an entire receptor molecule as a DNA binding domain, or can use portions of molecules that are capable of binding to nucleic acids, directly or indirectly.
- an electrophoretic mobility shift assay (EMSA) (Scott et al. (1994) J. Biol. Chem. 269: 19848-19858), in which a nucleic acid of interest is allowed to associate with various fragments of a polypeptide to identify those fragments that are capable of binding to the nucleic acid. Association of a portion of the protein with the nucleic acid will result in a retardation of the electrophoretic mobility of the nucleic acid.
- DNase I footprinting is well known to those of skill in the art.
- the DNA binding domain can be either a polypeptide or a nucleic acid.
- the nucleic acid will be capable of specifically hybridizing to a target nucleic acid site, such as a response element. Hybridization of the nucleic acid to the target site will place the chimeric receptor in a position suitable for activating or repressing expression of a gene that is linked to the target site.
- a target nucleic acid site such as a response element.
- Hybridization of the nucleic acid to the target site will place the chimeric receptor in a position suitable for activating or repressing expression of a gene that is linked to the target site.
- An example of an oligonucleotide being chemically linked to a protein by chemical coupling is found in Corey et al. (1989) Biochemistry 28: 8277-8286.
- chimeric receptors are useful, for example, in assays to identify modulators of FXR transcriptional regulation activity as described below.
- the assays of the invention typically use chimeric or non-chimeric FXR receptors in which the ligand binding domain is at least substantially identical to a ligand binding domain of an FXR polypeptide.
- the ligand binding domain and the DNA binding domain are linked together. Suitable methods of forming such linkages are known to those of skill in the art. For a review of methods for constructing fusion proteins between receptor ligand binding domains and DNA binding domains, see, e.g., Mattioni et al. (1994) Methods in Cell Biology 43(Pt A): 335-352.
- the linkage can be done using either recombinant or chemical methods. For example, a cysteine residue can be placed at either end of a domain so that the domain can be linked to another domain by, for example, a sulfide linkage.
- linkers are typically polypeptide sequences, such as poly glycine sequences of between about 5 and 200 amino acids, with between about 10-100 amino acids being typical.
- proline residues are incorporated into the linker to prevent the formation of significant secondary structural elements by the linker.
- Preferred linkers are often flexible amino acid subsequences which are synthesized as part of a recombinant fusion protein.
- the flexible linker is an amino acid subsequence comprising a proline such as Gly(x)-Pro-Gly(x) where x is a number between about 3 and about 100.
- a linker can also be a single peptide bond, or one or more amino acid residues.
- a chemical linker is used to connect synthetically or recombinantly produced ligand binding domain and DNA binding domain subsequences.
- Such flexible linkers are known to persons of skill in the art.
- poly(ethylene glycol) linkers are available from Shearwater Polymers, Inc. Huntsville, Ala. These linkers optionally have amide linkages, sulfhydryl linkages, or heterofunctional linkages.
- the chimeric receptors are conveniently produced by recombinant expression in a host cell.
- the invention provides chimeric nucleic acids that encode a fusion protein that includes a DNA binding domain and a ligand binding domain, at least one of which is at least substantially identical to the corresponding domain of an FXR of the invention.
- the chimeric nucleic acid will also encode a linker region that provides a link between the two domains.
- Techniques for making such chimeric nucleic acids are known to those of skilled in the art. For example, recombinant methods can be used (see, e.g., Berger and Sambrook, both supra.). Alternatively, the nucleic acid encoding the chimeric receptors can be synthesized chemically.
- a nucleic acid that encodes the chimeric receptor is generally placed under the control of a promoter and other control elements that can drive expression of the chimeric gene in a desired host cell.
- the invention also provides expression cassettes in which a promoter and/or other control elements are operably linked to a polynucleotide that encodes a chimeric receptor. Suitable promoters, other control sequences, and expression vectors are described above.
- the invention provides methods for identifying additional ligands for FXR.
- the identification of previously unknown FXR ligands is of particular interest not only for the knowledge obtained regarding the regulation of cholesterol metabolism, but also for identifying new compounds that can modulate FXR-mediated regulation of genes that are involved in cholesterol metabolism.
- Candidate ligands include not only bile acids and related compounds, but also transcription factors, coactivators, and corepressors with which FXR might interact. These potential ligands can include other receptor polypeptides (e.g., RXR, coactivators, and the like), which comprise the cellular machinery for regulation of gene expression. For example, nuclear hormone receptors often interact with transcriptional coactivators.
- the invention also provides methods of identifying coactivators, corepressors and other molecules that interact with FXRs. These assay methods can involve introducing a coactivator or a corepressor that is a candidate ligand for FXR into a host cell that contains a chimeric FXR and reporter plasmid.
- the coactivator can be introduced by means of an expression construct; this expression construct can be present on the same or a different vector than the expression construct for the chimeric receptor.
- Ligands for FXR can be identified using the methods described above for screening to identify compounds that modulate FXR interactions with the ligands. Instead of including a compound that potentially modulates the interaction, the assays are conducted using a potential FXR ligand. Both polypeptide-based and cell-based assays can be used.
- the present invention provides methods for obtaining response elements that are responsive to transcription complexes that include FXR. Through use of such methods, one can identify additional genes for which expression is modulated by the FXRs.
- the methods typically involve contacting a putative response element with a polypeptide that includes a FXR DNA binding domain (see, e.g., Ausubel et al., supra.). Both cell-based and biochemical methods are provided.
- a FXR receptor, or FXR DNA binding domain is used.
- the ligand binding domain is preferably one for which an appropriate ligand is available. Suitable chimeric receptors are described above.
- FXR can form a transcription regulatory complex with one or more other coactivators and/or corepressors. One or more of these other molecules can actually bind to the response element.
- FXR can bind to CPF, which in turn binds to a response element located upstream of the cyp7a gene.
- standard gel shift assays are performed to identify polynucleotides that can bind to a FXR DNA binding domain. These assays are performed by incubating a polypeptide that includes a FXR DNA binding domain, either as a purified protein or a complex mixture of proteins) with a labeled DNA fragment that contains the putative FXR binding site. Reaction products are analyzed on a nondenaturing polyacrylamide gel. To determine the specificity of the binding, one can perform competition experiments using polynucleotides that include a FXR binding site, or unrelated DNA sequences. Kits for performing gel shift assay include, for example, Gel Shift Assay Systems (Promega, Madison Wis., Part No. TB110).
- Another in vitro assay for identifying FXR response elements is the binding site selection method (see, e.g., U.S. Pat. No. 5,582,981).
- a library of oligonucleotides having a randomized nucleotide sequence of about 18 nucleotides flanked by two known nucleotide sequences of sufficient length to allow hybridization to PCR primers that are complementary to these regions.
- the oligonucleotides are end-labeled (e.g., with ⁇ - 32 P) and contacted with a FXR DNA binding domain polypeptide.
- a low stringency gel shift experiment is performed.
- PCR amplification is then carried out on those oligonucleotides to which the FXR DNA binding domain bound, as evidenced by retardation in the gel shift electrophoresis.
- the selection and amplification process is repeated at least twice more using the amplified fragments.
- In vivo assays for FXR response elements are also provided.
- the in vivo assays are particularly suitable for confirming results obtained in an in vitro assay.
- Cells are provided which contain a reporter construct that contains the putative response element in a position relative to a promoter at which binding of an FXR polypeptide can increase or decrease expression of an operably linked gene.
- the putative response element can be, for example, a member of a library of polynucleotide fragments.
- the chimeric receptor and the reporter constructs are introduced into a host cell. Suitable host cells are described in, for example, U.S. Pat. No. 5,071,773.
- the host cells that contain the reporter plasmid construct and the chimeric receptor are grown in the presence of the ligand for the ligand binding domain used in the chimeric receptor.
- Those cells in which expression of the reporter gene in the presence of the ligand is greater or less than the expression in the absence of the ligand contain a reporter construct that includes a putative response element for an FXR.
- the response elements can be isolated from these cells by, for example, plasmid recovery, PCR amplification, or other methods known to those of skill in the art. Upon isolation, the response elements can be characterized (e.g., by sequencing) and used to identify additional genes for which expression is influenced by FXRs.
- the invention provides compositions, kits and integrated systems for practicing the assays described herein.
- the invention provides an assay system that includes an FXR polypeptide and a ligand for FXR.
- assay systems for cell-based screening to identify FXR-modulating compounds typically include an expression vector for a full-length or chimeric FXR polypeptide, a vector that contains an appropriate reporter gene under the control of a transcription complex that includes FXR, and a suitable host cell is provided by the present invention.
- Ligands that bind to the ligand binding domain of FXR can also be included in the assay compositions, as can modulators of FXR activity.
- kits for practicing the FXR assay methods noted above can include any of the compositions noted above, and optionally further include additional components such as written instructions to practice a high-throughput method of assaying for FXR activity, or screening for an inhibitor or activator of FXR activity, one or more containers or compartments (e.g., to hold reagents, nucleic acids, or the like), and a control FXR activity modulator.
- the invention also provides integrated systems for high-throughput screening of potential FXR modulators for an effect on binding of FXR to ligands for FXR.
- the modulation of expression of genes that are under the control of FXR is tested.
- the systems typically include a robotic armature which transfers fluid from a source to a destination, a controller which controls the robotic armature, a label detector, a data storage unit which records label detection, and an assay component such as a microtiter dish comprising a well having a reaction mixture or a substrate.
- FXR-mediated disorders and conditions such as atherosclerosis, cardiovascular disorders, lipid disorders and hypercholesterolemia
- the candidate therapeutic agent is typically prepared as a pharmaceutical composition and is administered to a subject suffering from a FXR-mediated disorder or condition.
- the candidate therapeutic agents will, upon administration to the subject, cause total cholesterol levels to decrease about 10%, more preferably a decrease of about 20%, and most preferably a decrease of about 25-45%.
- compositions comprising a pharmaceutically acceptable carrier or excipient and a candidate therapeutic agent.
- Pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
- a solid carrier can be one or more substances which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
- the carrier is a finely divided solid which is in a mixture with the finely divided active component.
- the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
- the powders and tablets preferably contain from 5% or 10% to 70% of the active compound.
- Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
- the term “preparation” is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it.
- cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
- a low melting wax such as a mixture of fatty acid glycerides or cocoa butter
- the active component is dispersed homogeneously therein, as by stirring.
- the molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
- Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions.
- liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
- Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents as desired.
- Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
- solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration.
- liquid forms include solutions, suspensions, and emulsions.
- These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
- the pharmaceutical preparation is preferably in unit dosage form.
- the preparation is subdivided into unit doses containing appropriate quantities of the active component.
- the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
- the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
- the quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 1000 mg, preferably 1.0 mg to 100 mg according to the particular application and the potency of the active component.
- the composition can, if desired, also contain other compatible therapeutic agents.
- the present invention also provides methods of modulating FXR activity in a cell.
- a cell is contacted with an FXR-modulating amount of a compound or composition above.
- An FXR-modulating amount can be readily determined using the assays described briefly above, or alternatively, using the assays in the Examples below.
- Candidate therapeutic agents are especially useful in the treatment of hypercholesterolemia.
- the present invention provides methods of treating conditions modulated by FXR in a host animal, by administering to the host an effective amount of a compound or composition provided above.
- the compounds of the present invention can be prepared and administered in a wide variety of oral and parenteral dosage forms.
- the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally.
- the compounds described herein can be administered by inhalation, for example, intranasally.
- the compounds of the present invention can be administered transdermally.
- a variety of conditions are modulated, at least in part, by FXR, including hypercholesterolemia or other conditions associated with abnormal cholesterol or lipid homeostasis such as atherosclerosis, lipid disorders and cardiovascular disorders.
- the compounds utilized in the pharmaceutical method of the invention are administered at the initial dosage of about 0.001 mg/kg to about 100 mg/kg daily.
- a daily dose range of about 0.1 mg/kg to about 10 mg/kg is preferred.
- the dosages may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.
- the host or subject in each of these methods is human, although other animals can also benefit from the foregoing treatments.
- CDCA Specifically Transactivates FXR
- This Example demonstrates that the primary bile acid chenodeoxycholic acid (CDCA) specifically activates the gene expression regulatory activity of FXR.
- the experiment was conducted using fusion polypeptides in which a ligand binding domain of FXR and other nuclear receptors were independently linked to the DNA binding domain (DBD) of Gal4.
- DBD DNA binding domain
- LBDs ligand-binding domains
- HepG2 cells were transiently transfected with a reporter plasmid in which a luciferase-encoding gene was under the control of a pGL3 5 ⁇ GAL4 response element (which consists of five GAL4 binding elements) (0.25 ⁇ g/1.5 ⁇ 10 5 cells).
- the cells were also transfected with the empty expression vector pM3 or the pM3-LBD fusion expression plasmids (0.25 ⁇ g/1.5 ⁇ 10 5 cells) as indicated. Luciferase reporter activity was measured after treating cells with or without 50 ⁇ M CDCA.
- fold activation is a ratio of luciferase activity (normalized by ⁇ -galactosidase activity) between treated and untreated cells.
- the FXR fusion construct was the sole receptor transactivated by CDCA (see, FIG. 1A).
- This example further illustrates that CDCA-mediated transactivation of FXR is dose-dependent.
- HepG2 cells were transiently transfected with the pGL3 3 ⁇ FXRE (three FXR response elements, AGGTCAATGACCT) luciferase reporter plasmid (0.25 ⁇ g/1.5 ⁇ 10 5 cells), plus empty expression vector (pcDNA3) or a plasmid expressing full-length FXR (pFXR) (0.15 ⁇ g/1.5 ⁇ 10 5 cells). Luciferase reporter activity was measured after treating cells with or without CDCA (concentrations as indicated).
- Fold activation was calculated as the ratio of luciferase activity (normalized by ⁇ -galactosidase activity) between treated and untreated cells.
- a dose-dependent transactivation (IC 50 10 ⁇ M CDCA) of the reporter gene by FXR was observed (see, FIG. 1B).
- This example illustrates that CDCA-mediates FXR-specific suppression of CYP7 expression.
- Full-length nuclear receptors FXR, CPF, HNF4 ⁇ , LXR ⁇ and RXR ⁇ were assayed to determine their ability to suppress CYP7 expression in the presence of 10 ⁇ M CDCA.
- a luciferase reporter plasmid under the control of the cyp7a promoter ( ⁇ 718 to +14, where +1 designates the transcriptional start site) (pGL3-CYP7) was used.
- HepG2 cells were transiently transfected with the pGL3-CYP7 luciferase reporter (0.25 ⁇ g/1.5 ⁇ 10 5 cells) plus empty expression vector (pcDNA3) or plasmids expressing one of the indicated nuclear receptors (0.25 ⁇ g/1.5 ⁇ 10 5 cells).
- Luciferase reporter activity was measured after treating cells with or without 10 ⁇ M CDCA.
- the ratio of luciferase activity (normalized by ⁇ -galactosidase activity) between treated and untreated pcDNA3-transfected cells was set at 100 percent CYP7 expression.
- the percent CYP7 expression for the nuclear receptors was normalized to that of pcDNA3. Only FXR suppressed CYP7 expression under these conditions (see, FIG. 2A).
- This example further illustrates the dose response profile of CDCA-mediated suppression of CYP7 expression by FXR.
- HepG2 cells were transiently transfected with the pGL3-CYP7 luciferase reporter plasmid (0.25 ⁇ g/1.5 ⁇ 10 5 cells), plus empty expression vector (pcDNA3) or a plasmid expressing full-length FXR (pFXR) (0.15 ⁇ g/1.5 ⁇ 10 5 cells). Luciferase reporter activity was measured after treating cells with or without CDCA (concentrations as indicated). The presence of FXR alone suppresses CYP7 expression, and this suppression is enhanced with the addition of CDCA (see, FIG. 2B).
- This example illustrates that CDCA-mediated FXR suppression is specific for CYP7.
- FXR does not suppress expression of the low density lipoprotein (LDL) receptor.
- LDL low density lipoprotein
- This experiment was conducted using a second luciferase reporter plasmid, named p-6500, in which the luciferase gene is under the control of a 6.5 kilobase pair (kb) promoter region of the LDL receptor.
- HepG2 cells were transiently transfected with pGL3-CYP7 or p-6500.
- Cells were also transfected with either empty expression vector (pcDNA3) or a plasmid that expresses full-length FXR (pFXR) (all at 0.25 ⁇ g/1.5 ⁇ 10 5 cells).
- Luciferase reporter activity was measured after treating cells with or without 10 ⁇ M CDCA. The ratio of luciferase activity (normalized by ⁇ -galactosidase activity) between treated and untreated pcDNA3-transfected cells was set at 100 percent CYP7 expression. No FXR/CDCA-mediated suppression of the p-6500 reporter was observed (see, FIG. 3A).
- This example further illustrates that CYP7 suppression is lost upon titrating away FXR.
- HepG2 cells were transiently transfected with pGL3-CYP7 luciferase reporter plasmid (50 ng/1.5 ⁇ 10 5 cells), plus an empty expression vector (pcDNA3) or a plasmid expressing full-length FXR (pFXR) (0.25 ⁇ g/1.5 ⁇ 10 5 cells).
- Cells were also transfected with a competitor plasmid, either pBSKS or pGL3 3 ⁇ FXRE Aluc (0.5 ⁇ g/1.5 ⁇ 10 5 cells). Luciferase reporter activity was measured after treating cells with or without 10 ⁇ M CDCA.
- the ratio of luciferase activity (normalized by ⁇ -galactosidase activity) between treated and untreated pcDNA3-transfected cells was set at 100 percent CYP7 expression. Loss of CYP7 suppression was observed when ten-fold excess pGL3 3 ⁇ FXR Aluc was cotransfected with the CYP7 reporter gene (see, FIG. 3B). This result strongly suggests that FXR is a component of the bile acid-mediated suppression of CYP7.
- FXR mutants do not suppress CYP7 expression.
- FXR mutants were created and assayed to determine whether they are able to suppress CYP7 in a CDCA-dependent manner.
- HepG2 cells were transiently transfected with the pGL3-CYP7 luciferase reporter plasmid (0.25 ⁇ g/1.5 ⁇ 10 5 cells), plus empty expression vector (pcDNA3) or a plasmid expressing full-length wild-type FXR (pFXR) or mutant (DNA-binding domain [DBD], ligand-binding domain [pLBD], and AF2 domain truncation [dAF2]) FXR (0.25 ⁇ g/1.5 ⁇ 10 5 cells).
- Luciferase reporter activity was measured after treating cells with or without 10 ⁇ M CDCA.
- the ratio of luciferase activity (normalized by ⁇ -galactosidase activity) between treated and untreated pcDNA3-transfected cells was set at 100 percent CYP7 expression. None of the FXR derivatives had any effect upon CYP7 suppression (see, FIG. 3C).
- This example demonstrates that bile acids and FXR repress expression from the promoter for the cholesterol 7 ⁇ -hydroxylase (Cyp7A) gene, which is the rate-limiting enzyme in cholesterol metabolism.
- Cyp7A cholesterol 7 ⁇ -hydroxylase
- mRNA mRNA
- the medium was replaced with DMEM-F12 without serum, and supplemented with primary or conjugated bile acids at a final concentration of 50 ⁇ M. The cultures were then incubated at 37° C., 5% CO 2 for 24 hours.
- CYP7 ⁇ 78 5′-tgatttgggggattgctata-3′
- CYP7 ⁇ 178 5′-catacctgggctgtgctct-3′
- CYP7 ⁇ 132 5′-(6-FAM)tggttcacccgtttgccttctct(TAMRA)-3′.
- a primer set for detection of human GAPDH mRNA was used; this set is commercially available and was obtained from Applied Biosystems/Perkin Elmer, Inc.
- Amplification of specific target mRNAs was carried out by reverse transcription followed by polymerase chain reaction using the TaqMan One Step Gold RT-PCR Kit (Applied Biosystems/Perkin Elmer, Inc.). Each primer set included a pair of amplification primers and the fluorogenic probe primer as indicated, and were present in the reaction at a final concentration of 100 nM/primer. One ⁇ g of total RNA isolated from the various culture conditions was used as template in individual RT-PCR reactions.
- Luciferase reporter activity was measured after treating cells with or without the panel of bile acids (concentrations as indicated) (FIG. 4B).
- Relative luciferase activity is a ratio of luciferase activity (normalized by ⁇ -galactosidase activity) between treated and untreated cells.
- CDCA treatment resulted in the largest induction of luciferase activity (see, FIGS. 4B and 4C), and also the largest repression of CYP7a expression (FIG. 4D).
- the rank order of bile acids in these activity-measuring experiments was the same as that for repressing endogenous expression of human Cyp7a protein and mRNA (FIG. 4A)
- This Example describes three different high throughput in vitro assay that are useful for screening to identify compounds that can modulate binding of FXR ligands to the FXR ligand binding domain.
- the ability of different bile acids and derivatives to affect the binding of a labeled sensor peptide that is derived from the coactivator SRC-1 to an FXR ligand binding domain was tested.
- Fluorescence polarization was used to study the effect of different bile acids on the ability of the FXR LBD to bind a sensor peptide.
- the assay reagents were as follows:
- Buffer 10 mM HEPES, 10 mM NaCl, 6 mM magnesium chloride, pH 7.6
- FIG. 5B shows the results of an experiment in which fluorescence resonance energy transfer (FRET; also referred to as HTRF) was used to study the effect of different bile acids on the ability of FXR to bind the coactivator SRC-1.
- FRET fluorescence resonance energy transfer
- the top panel shows that FXR-SRC-1 binding is stimulated by bile acids.
- the bottom panel of FIG. 5B shows that the binding of the LXR ⁇ receptor control is affected not by the bile acids, but rather by the LXR ⁇ ligand 24,25 epoxycholesterol.
- the orphan nuclear receptor FXR is involved in the bile acid-dependent suppression of the human cyp7 gene.
- IC 50 10 M
- Overexpression of FXR was found to suppress cyp7 expression and the suppression was enhanced in the presence of CDCA. This enhanced suppression is specifically mediated by FXR and seems to be specific to the cyp7 promoter.
- a panel of bile acids it was demonstrated that the bile acid-mediated FXR activation correlates with bile acid-mediated human cyp7 suppression.
Abstract
Description
- This application claims benefit of U.S. Provisional Patent Application No. 60/115,249, which was filed on Jan. 7, 1999, which application is incorporated herein by reference for all purposes.
- 1. Field of the Invention
- This invention relates to methods and compounds for the modulation of cholesterol metabolism in a mammal and methods for screening to identify candidate therapeutic agents for modulation of cholesterol levels.
- 2. Background
- Atherosclerosis is a leading cause of death, myocardial infarctions, stroke, peripheral vascular disease and cardiovascular disease (Libby, in Chapter 242 ofHarrison 's Principles of Internal Medicine, 14th edition (1998) (Fauci et al., eds.); Witztum, in Chapter 36 of Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th edition (1996) (Hardman et al., eds.)). One of the major contributing factors to atherosclerosis is hypercholesterolemia. Hypercholesterolemia is currently treated with a combination of dietary and pharmaceutical therapies. Often more than a single pharmaceutical agent and a dietary regimen are necessary to decrease total cholesterol and LDL cholesterol levels to the desired level. Drugs such as bile acid sequestrants, niacin and the statins are commonly used to treat hypercholesterolemia and atherosclerosis. The use of niacin, however, is limited by the high incidence (>50%) of numerous side effects that are experienced in patients. Thus, a need for therapeutic agents that would decrease cholesterol levels still exists.
- Cholesterol homeostasis in mammals is maintained through the coordinate regulation of three major pathways in the liver. Two pathways supply cholesterol to cells and include an endogenous biosynthetic pathway in which acetate is converted into cholesterol and an exogenous pathway in which members of the low-density lipoprotein receptor family bind and internalize cholesterol-carrying particles from the blood. A third pathway involves the conversion of cholesterol into hydrophilic bile acids.
- The conversion of cholesterol to bile acids involves a minimum of fourteen enzymes of the bile acid biosynthetic pathway. The first and rate-limiting enzymatic reaction of this pathway is catalyzed by the enzyme cholesterol 7α-hydrolase. The cholesterol 7α-hydrolase gene, also known as cyp7A, belong to the cytochrome P-450 family that contains many microsomal enzymes involved in liver metabolism. It has been shown that expression of the cyp7A gene is tightly regulated. This gene is expressed exclusively in the liver and its expression can be induced by dietary cholesterol and suppressed by bile acids. An alternative pathway involves the cyp7B gene, which is expressed in the brain as well as other tissues. It has been shown that cholesterol catabolism plays a central role in cholesterol homeostasis. For instance, treatment of laboratory animals with cholestid or cholestyramine, two bile acid-binding resins, decreases serum cholesterol levels. Moreover, overexpression of the cyp7 gene in hamsters reduces both total cholesterol levels and LDL cholesterol levels. As such, cholesterol 7α-hydrolase is a potential therapeutic target for the identification of cholesterol reducing compounds and, thus, understanding the mechanism by which expression of the cyp7 genes are regulated is of particular importance.
- Nuclear receptors form a large family of ligand-activated transcription factors that modify the expression of target genes by binding to specific cis-acting sequences (Laudet et al. (1992)EMBO J. 11: 1003-1013; Lopes da Silva et al. (1995) Trends Neurosci. 18: 542-548; Mangelsdorf et al. (1995) Cell 83: 835-839; Mangelsdorf and Evans (1995) Cell 83: 841-850). Nuclear receptors include those that remain sequestered in the cytoplasm in the absence of their cognate ligands (e.g., steroid hormone receptors). Upon binding of the ligand, the steroid hormone receptors are translocated to the nucleus where they bind to hormone response elements, typically as homodimers.
- Most of the nuclear receptors, conversely, are not sequestered in the cytoplasm in the absence of their ligands but rather remain in the nucleus. These receptors, which include the thyroid hormone, retinoid, fatty acid, and eicosanoid receptors, typically bind to their cognate response elements as heterodimers with a 9-cis-retinoic acid receptor (RXR). Often, binding of a nuclear receptor to a response element occurs in the absence of the cognate ligand.
- One such nuclear receptor is the famesoid X receptor (FXR; also known as “
RIP 14” and “NR1H4”) (Forman et al. (1995) Cell 81: 687; Seol et al. (1995) Mol. Endocrinol. 9: 72; Mangelsdorf and Evans, supra.). FXR functions as a heterodimer with RXR, and several isoprenoid lipids can weakly activate FXR at supraphysiological concentration; however, these compounds do not activate all species of FXR and do not bind as ligands (Forman et al., supra.; Zavacki et al. (1997) Proc. Nat'l. Acad. Sci. USA 94: 7909). Thus, the identity and physiologic function of FXR ligands have remained unknown. - The lack of understanding of physiological mechanisms that regulate cholesterol levels has hampered the discovery of improved methods of treating hypercholesteremia. Thus, a need exists for characterization of regulatory mechanisms of cholesterol hemostasis, and for screening methods to identify better compounds for treating hypercholesteremia. The present invention fulfills these and other needs.
- The present invention is based in part on the discovery that the orphan nuclear receptor FXR (famesoid X receptor) is involved in the suppression of the human cyp7 genes. More particularly, it has been discovered that FXR functions as a bile acid receptor/sensor that mediates cyp7 expression in a bile-acid dependent manner. As such, in one aspect, the present invention provides a method for increasing cholesterol metabolism in a cell by contacting the cell with a compound that modulates the binding of an FXR to a ligand for FXR. In one embodiment, the ligand is a bile acid. In another embodiment, the compound modulates the binding of the FXR to an RXR or other coactivator or corepressor.
- The invention provides methods for prescreening to identify a candidate therapeutic compound suitable for testing for ability to modulate cholesterol metabolism in a cell. These methods involve:
- providing a reaction mixture that comprises:
- a) a polypeptide that comprises a ligand binding domain of an FXR;
- b) a ligand for FXR; and
- c) a test compound; and
- determining whether the amount of binding of the FXR ligand binding domain to the ligand for FXR is increased or decreased in the presence of the test compound compared to the amount of binding in the absence of the test compound. A test compound that causes an increase or decrease in binding is a candidate therapeutic agent for modulation of cholesterol metabolism. In some embodiments, the methods further involve administering the candidate therapeutic agent to a cell to determine whether the candidate therapeutic agent modulates cholesterol metabolism in the cell.
- The invention also provides methods for screening to identify a compound that modulates cholesterol metabolism in a cell using a gene expression assay. For example, these methods can involve contacting a cell with a test compound, wherein said cell includes:
- a) a polynucleotide that encodes a polypeptide comprising: 1) a DNA binding domain of a receptor which binds to DNA; and 2) a ligand binding domain that is substantially identical to a ligand binding domain of a FXR;
- b) a ligand for FXR; and
- c) a reporter gene construct which comprises a response element to which said DNA binding domain can bind, wherein said response element is operably linked to a promoter that is operative in the cell and said promoter is operably linked to a reporter gene.
- By determining whether the reporter gene is expressed at a higher or lower level in the presence of said test compound compared to said reporter gene expression level in the absence of said test compound, one can identify a test compound that can modulate cholesterol metabolism in a cell. The cells used in the methods of the invention are typically mammalian cells. In a presently preferred embodiment, the cell is in a mammal and, in particular, in a human.
- The test compounds are, in some embodiments, a compound that binds to FXR or to the ligand for FXR, and thus inhibits binding of the ligand to the FXR. For example, the compound can be an antibody that binds to FXR, or an organic molecule that interferes with the interaction. The binding of the compound can also modulate the binding of a transcription complex that comprises FXR to a response element. Response elements of particular interest include those that are derived from a region upstream of a cyp7 gene.
- In another embodiment, the present invention provides a method for reducing cholesterol levels in a mammal. These methods involve administering to said mammal a compound that modulates the binding of an FXR to an FXR response element. In a preferred embodiment, the mammal is a human.
- The invention also provides assays for identifying ligands for FXR, and response elements that are bound by FXR or by a transcription complex that includes FXR.
- FIGS. 1A and 1B illustrate that the bile acid CDCA specifically transactivates FXR. FIG. 1A illustrates that a GAL4 DNA binding domain fused to an FXR ligand binding domain is activated by CDCA, while ligand binding domains of other nuclear receptors fused to the GAL4 DBD are not activated by CDCA. FIG. 1B illustrates that CDCA-mediated transactivation of FXR is dose-dependent.
- FIGS. 2A and 2B illustrate that FXR suppresses cyp7 expression. FIG. 2A illustrates that CDCA-mediated suppression of cyp7 is specific to FXR. FIG. 2B illustrates a dose-response profile of CDCA-mediated suppression of cyp7 expression by FXR.
- FIGS. 3A, 3B and3C illustrate that FXR suppression is specific to cyp7. FIG. 3A illustrates that FXR does not suppress expression of the low density lipoprotein (LDL) receptor. FIG. 3B illustrates that titrating away FXR causes a loss of cyp7 suppression. FIG. 3C illustrates that FXR mutants do not suppress cyp7 expression.
- FIGS. 4A and 4B,4C and 4D illustrate the effect of different bile acids on FXR activity. FIG. 4A illustrates a western blot analysis of cyp7 expression, as well as a quantitative RT-PCR analysis of cyp7 mRNA in HepG2 cells. FIG. 4B illustrates that FXR interacts with the co-activator SRC-1 in a mammalian two-hybrid assay. FIG. 4C shows the effect of different bile acids on FXR-mediated transactivation. FIG. 4D shows the effect of the bile acids on FXR-mediated suppression of cyp7 expression.
- FIG. 5A illustrates the results of a peptide sensor assay using a GST-FXR fusion protein. The binding of the peptide sensor to the FXR LBD in the presence of different bile acids and derivatives was analyzed by fluorescence polarization. FIG. 5B shows the results of an analysis in which FRET was used to monitor the effect of bile acids and derivatives on FXR/SRC-1 interaction. FIG. 5C shows the results of a sensor peptide study in which ELISA was used to detect binding of the sensor peptide to the FXR LBD in the presence of increasing concentrations of different bile acids and derivatives.
- The following definitions are used herein.
- Definitions
- The term “isolated” refers to material that is substantially or essentially free from components which normally accompany the enzyme as found in its native state. Thus, the polypeptides of the invention do not include materials normally associated with their in situ environment. Typically, isolated proteins of the invention are at least about 80% pure, usually at least about 90%, and preferably at least about 95% pure as measured by band intensity on a silver stained gel or other method for determining purity. Protein purity or homogeneity can be indicated by a number of means well known in the art, such as polyacrylamide gel electrophoresis of a protein sample, followed by visualization upon staining. For certain purposes high resolution will be needed and HPLC or a similar means for purification utilized.
- The term “recombinant” when used with reference to a cell, or nucleic acid, or vector, indicates that the cell, or nucleic acid, or vector, has been modified by the introduction of a heterologous nucleic acid or the alteration of a native nucleic acid, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all.
- The terms “identical” or percent “identity,” in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual alignment and inspection.
- The phrase “substantially identical,” in the context of two nucleic acids or polypeptides, refers to two or more sequences or subsequences that have at least 75%, preferably 85%, most preferably 90-95% nucleotide or amino acid residue identity, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection. Preferably, the substantial identity exists over a region of the sequences that is at least about 50 residues in length, more preferably over a region of at least about 100 residues, and most preferably the sequences are substantially identical over at least about 150 residues. In a most preferred embodiment, the sequences are substantially identical over the entire length of the coding regions and/or untranslated regions.
- A further indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules hybridize to each other under stringent conditions, as described below.
- “Bind(s) substantially” refers to complementary hybridization between a probe nucleic acid and a target nucleic acid and embraces minor mismatches that can be accommodated by reducing the stringency of the hybridization media to achieve the desired detection of the target polynucleotide sequence.
- The phrase “hybridizing specifically to”, refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent conditions when that sequence is present in a complex mixture (e.g., total cellular) DNA or RNA. The term “stringent conditions” refers to conditions under which a probe will hybridize to its target subsequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. Generally, stringent conditions are selected to be about 5° C. lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength, pH, and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. (As the target sequences are generally present in excess, at Tm, 50% of the probes are occupied at equilibrium). Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M Na+, typically about 0.01 to 1.0 M Na+ concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30° C. for short probes (e.g., 10 to 50 nucleotides) and at least about 60° C. for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.
- The phrase “specifically or selectively binds to an antibody” or “specifically immunoreactive with”, when referring to a protein or peptide, refers to a binding reaction which is determinative of the presence of the protein in the presence of a heterogeneous population of proteins and other biologics. Thus, under designated assay conditions, the specified antibodies or other ligand bind to a particular protein and do not bind in a significant amount to other proteins present in the sample. Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular protein. For example, antibodies raised to the FXR polypeptides (or subsequences thereof) or to the polypeptides partially encoded by the FXR polynucleotide sequences can be selected to obtain antibodies specifically immunoreactive with the full length proteins and not with other proteins, except perhaps to polymorphic variants. A variety of immunoassay formats can be used to select antibodies and other molecules that specifically bind to a particular protein such as FXR. For example, solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically immunoreactive with a protein. See, e.g., Harlow and Lane (1988)Antibodies, A Laboratory Manual, Cold Spring Harbor Publications, New York, for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity. Typically a specific or selective reaction will be at least twice background signal or noise and more typically more than 10 to 100 times background.
- The present invention pertains to the discovery that ligands for the formerly orphan receptor FXR include bile acids, and that the binding of a bile acid to FXR results in suppression of cholesterol catabolism. Accordingly, the invention provides methods for modulating (i.e., increasing or decreasing) cholesterol levels in a cell by contacting the cell with a compound that modulates the binding of FXR to ligand for FXR. By decreasing binding of the FXR to an FXR ligand, for example, a compound can reduce the suppression of a gene such as cyp7 (i.e., increase the expression) which encodes an enzyme that is a key enzyme in cholesterol metabolism. Also provided by the invention are methods for increasing or decreasing cholesterol levels in a mammal, including humans by administering to the mammal a compound that modulates the binding of FXR to an FXR ligand. In other embodiments, the invention provides methods for identifying compounds that can modulate cholesterol metabolism by, for example, altering the ability of FXR to bind to FXR ligands.
- A. Assays for Identifying Compounds that Modulate Cholesterol Metabolism
- The invention also provides screening assays for identifying compounds that can modulate cholesterol metabolism. These compounds can function by, for example, altering the interaction between FXR and FXR ligands (e.g., bile acids, corepressors and/or coactivators) and/or between FXR and its response elements. Of particular interest is the modulation of cyp7 gene expression, which is inhibited by binding of FXR to the upstream region of the gene. Thus, a compound that inhibits the cis-repressing activity of FXR can increase the expression of cyp7, thus increasing degradation of cholesterol. Compounds that are identified using the screening methods of the invention find use in studies of gene regulation, and also find therapeutic use in situations in which it is desirable to increase or decrease cholesterol metabolism. Other uses will also be apparent those of ordinary skill in the art.
- The assays of the invention are amenable to screening of large chemical libraries by automating the assay steps and providing compounds from any convenient source to assays, which are typically run in parallel (e.g., in microtiter formats on microtiter plates in robotic assays). Essentially any chemical compound can be used as a potential FXR activity modulator in the assays of the invention. In some embodiments, compounds that can be dissolved in aqueous or organic (especially DMSO-based) solutions are used. It will be appreciated that there are many suppliers of chemical compounds, including Sigma (St. Louis, Mo.), Aldrich (St. Louis, Mo.), Sigma-Aldrich (St. Louis, Mo.), Fluka Chemika-Biochemica Analytika (Buchs Switzerland) and the like.
- In one preferred embodiment, high throughput screening methods involve providing a combinatorial library containing a large number of potential therapeutic compounds (potential modulator compounds). Such “combinatorial chemical libraries” are then screened in one or more assays, as described herein, to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity (e.g., inhibit the interaction between FXR and an FXR ligand). The compounds thus identified can serve as conventional “lead compounds” or “candidate therapeutic agents,” or can themselves be used as potential or actual therapeutics.
- A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis, by combining a number of chemical “building blocks” such as reagents. For example, a linear combinatorial chemical library such as a polypeptide library is formed by combining a set of chemical building blocks (amino acids) in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks.
- Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Pat. No. 5,010,175, Furka,Int. J. Pept. Prot. Res. 37:487-493 (1991) and Houghton et al., Nature 354:84-88 (1991)). Other chemistries for generating chemical diversity libraries can also be used. Such chemistries include, but are not limited to: peptoids (PCT Publication No. WO 91/19735), encoded peptides (PCT Publication WO 93/20242), random bio-oligomers (PCT Publication No. WO 92/00091), benzodiazepines (U.S. Pat. No. 5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs et al., Proc. Nat. Acad. Sci. USA 90:6909-6913 (1993)), vinylogous polypeptides (Hagihara et al., J. Amer. Chem. Soc. 114:6568 (1992)), nonpeptidal peptidomimetics with β-D-glucose scaffolding (Hirschmann et al., J. Amer. Chem. Soc. 114:9217-9218 (1992)), analogous organic syntheses of small compound libraries (Chen et al., J. Amer. Chem. Soc. 116:2661 (1994)), oligocarbamates (Cho et al., Science 261:1303 (1993)), and/or peptidyl phosphonates (Campbell et al., J. Org. Chem. 59:658 (1994)), nucleic acid libraries (see, Ausubel, Berger and Sambrook, all supra), peptide nucleic acid libraries (see, e.g., U.S. Pat. No. 5,539,083), antibody libraries (see, e.g., Vauglui et al., Nature Biotechnology, 14(3):309-314 (1996) and PCT/US96/10287), carbohydrate libraries (see, e.g., Liang et al., Science, 274:1520-1522 (1996) and U.S. Pat. No. 5,593,853), small organic molecule libraries (see, e.g., benzodiazepines, Baum C&EN, January 18, page 33 (1993); isoprenoids, U.S. Pat. No. 5,569,588; thiazolidinones and metathiazanones, U.S. Pat. No. 5,549,974; pyrrolidines, U.S. Pat. Nos. 5,525,735 and 5,519,134; morpholino compounds, U.S. Pat. No. 5,506,337; benzodiazepines, U.S. Pat. No. 5,288,514, and the like).
- Devices for the preparation of combinatorial libraries are commercially available (see, e.g., 357 MPS, 390 MPS, Advanced Chem Tech, Louisville Ky., Symphony, Rainin, Wobum, Mass., 433A Applied Biosystems, Foster City, Calif., 9050 Plus, Millipore, Bedford, Mass.). In addition, numerous combinatorial libraries are themselves commercially available (see, e.g., ComGenex, Princeton, N.J., Asinex, Moscow, Ru, Tripos, Inc., St. Louis, Mo., ChemStar, Ltd, Moscow, RU, 3D Pharmaceuticals, Exton, Pa., Martek Biosciences, Columbia, Md., etc.).
- The invention provides both biochemical and cell-based assays for identifying compounds that can modulate FXR-mediated regulation of cholesterol metabolism. Often, an initial assay is performed in vitro to identify compounds that are potential candidate therapeutic agents, after which such compounds are then tested in vivo by, for example, administering the compound to a test animal to determine whether cholesterol levels are affected.
- 1. Direct and Displacement Assays
- The invention provides methods for identifying compounds that are suitable for further testing as candidate therapeutic agents for treatment of hypercholesteremia and other conditions that are associated with cholesterol synthesis and metabolism. Compounds that exhibit the desired activity in the in vitro assays can be used for further studies of the regulation of pathways involved in cholesterol hemostasis, or can be subjected for further testing to identify those that are suitable for use to treat hypercholesterolemia or other conditions involving cholesterol metabolism.
- One type of assay that can be used is a direct binding assay, which measures the amount of a compound that can bind to an FXR polypeptide or to a polypeptide that has an FXR ligand binding domain. These assays can be carried out using labeled candidate therapeutic agents which are then incubated with a polypeptide that has an FXR ligand binding domain (e.g., a full-length FXR polypeptide or a fusion protein). Labels include radioisotopes, immunochemicals, fluorophores, and the like. Those of skill in the art will recognize a variety of ways of separating the bound labeled candidate therapeutic agent from the free labeled candidate therapeutic agent. The affinity of the labeled candidate therapeutic agent for an FXR polypeptide can be calculated using standard ligand binding methods.
- Another type of assay that can be used to pre-screen candidate therapeutic agents involves testing the ability of a test compound to modulate binding of FXR to a ligand for FXR. These can be conducted, for example, as a direct binding assay with a labeled FXR ligand in the presence of a candidate therapeutic agent. The assays involve placing the test compound into an assay mixture that includes at least a ligand binding domain of an FXR polypeptide and a ligand for FXR. The effect on binding of the FXR ligand to FXR is determined. A test compound that decreases the amount of labeled FXR ligand that is bound to an FXR polypeptide or a polypeptide that has an FXR ligand binding domain, is of interest for future screening for its ability to modulate cholesterol levels in vivo.
- Ligands that are suitable for use in the assays of the invention include, but are not limited to, bile acids and related compounds such as CDCA (chenodeoxycholic acid), GCDCA (glycochenodeoxycholic acid), TCDCA (taurochenodeoxycholic acid), GCA (glycocholic acid), TCA (taurocholic acid), DCA (deoxycholic acid), LCA (lithocholic acid), DHCA (dehydrocholic acid), UDCA (ursodeoxycholic acid) and CA (cholic acid). In a presently preferred embodiment, the bile acid is CDCA. Additional bile acids and other ligands are described in, for example, Makishima et al. (1999)Science 284: 1362-1365. The assays can also employ coactivators and corepressors with which FXR interacts. Methods of identifying FXR ligands are described below.
- In presently preferred embodiments, an assay such as the fluorescence polarization assay or the fluorescence resonance energy transfer assay is employed to identify candidate therapeutic agents. These assays do not require the separation of bound and free labeled test compound. Fluorescence polarization (FP) or fluorescence anisotropy is a useful tool for the study of molecular interactions (see, e.g. http://www.panvera.com/tech/appguide/fpintro.html, Nov. 4, 1999). First, a molecule labeled with a fluorophore is excited with plane polarized light. If the fluorescent molecule stays stationary while in the excited state, light is emitted in the same polarized plane. If the excited fluorescently labeled molecule rotates out of the plane of the polarized light while in the excited state, light is emitted from the molecule in a different plane. For example, if vertical polarized light is used to excite the fluorophore, the emission spectra can be monitored in the vertical and horizontal planes. Fluorescence polarization is calculated as shown in the following Formula I:
- Fluorescent polarization=P=(Int ∥−Int⊥)/(Int ∥+Int⊥) I
- In Formula I, Int ∥ is the intensity of the emission parallel to the excitation plane. Int⊥ is the intensity of the emission perpendicular to the excitation plane.
- A small fluoreseently labeled molecule, when free in solution, can emit depolarized light when excited with the proper wavelength of light. If, however, the molecule (e.g., a ligand) binds to a second molecule (e.g., a receptor) the fluorescently labeled molecule is more constrained so the light emitted is more polarized and the fluorescence polarization (FP) value is higher. Thus, a higher FP value indicates that the fluorescently labeled molecule is able to bind to the second molecule. A competition assay also can be performed using FP. If an unlabeled molecule is present in the solution, then it will compete for binding to the second molecule, e.g., the antibody and the FP value will be decreased. Thus, FP can be used in competitive assays.
- Commercial assays exist to test the affinity of compounds for human estrogen receptor α and β using a fluorescently labeled estrogen compound (see, Panvera, (Madison, Wis.) publications Lit.#'s L0069, L0082, L0084, L0095, L0072, L0085). Similarly, test compounds can be fluorescently labeled with a fluorophore that is active in a FP assay. For example, N-terminal amines of proteins, peptide, or peptide analogs can be labeled with fluorescein (Panvera, publications Lit. # L0057 and L0059) or a small fluorescent compound. Briefly, a fluorescein-C6-succinimidyl ester can be conjugated to peptides or proteins. The fluorescein labeled peptide/protein can then be purified from the unreacted fluorescein-C6-succinimidyl ester using thin-layer chromatography or gel filtration chromatography. If the labeled test compound can bind to a polypeptide that has an FXR ligand binding domain, the level of polarization is increased. The FP assay also can be used to assay the ability of a fluorescently labeled FXR ligand to bind to an FXR polypeptide.
- Alternatively, a test compound can be screened for its ability to decrease the FP of a fluorescently labeled known FXR ligand complexed with an FXR polypeptide or a polypeptide comprising an FXR ligand binding domain. Briefly, a known FXR ligand is labeled with a fluorescent moiety. A test compound that decreases the FP value of the fluorescently labeled FXR ligand and FXR is displacing or inhibiting the ability of the fluorescently labeled FXR ligand to bind to the ligand binding domain of FXR.
- Methods employing the technique of fluorescence resonance energy transfer (FRET) can be employed using the methods and compositions of the present invention. FRET occurs between two fluorophores when the excitation of the donor fluorophore is transferred to the acceptor fluorophore. This interaction is dependent on the distance between the donor and acceptor fluorophore and distance-dependent interaction between a donor and acceptor molecule. The donor and acceptor molecules are fluorophores. If the fluorophores have excitation and emission spectra that overlap, then in close proximity (typically around 10-100 angstroms) the excitation of the donor fluorophore is transferred to the acceptor fluorophore. The relative proximity of the first and second labels is determined by measuring a change in the intrinsic fluorescence of the first or second label. Commonly, the emission of the first label is quenched by proximity of the second label.
- Many appropriate interactive labels for FRET are known. For example, fluorescent labels, dyes, enzymatic labels, and antibody labels are all appropriate. Examples of preferred interactive fluorescent label pairs include terbium chelate and TRITC (tetrarhodamine isothiocyanate), europium cryptate and allophycocyanin and many others known to one of skill. Similarly, two colorimetric labels can result in combinations that yield a third color, e.g., a blue emission in proximity to a yellow emission produces an observed green emission.
- With regard to preferred fluorescent pairs, there are a number of fluorophores which are known to quench each other. Fluorescence quenching is a bimolecular process that reduces the fluorescence quantum yield, typically without changing the fluorescence emission spectrum. Quenching can result from transient excited interactions, (collisional quenching) or, e.g., from the formation of nonfluorescent ground state species. Self-quenching is the quenching of one fluorophore by another; it tends to occur when high concentrations, labeling densities, or proximity of labels occurs. Some excited fluorophores interact to form excimers, which are excited state dimers that exhibit altered emission spectra (e.g., phospholipid analogs with pyrene sn-2 acyl chains); See Haugland (1996)Handbook of Fluorescent Probes and Research Chemicals, published by Molecular Probes, Inc., Eugene, Oreg.
- The Forster radius (Ro) is the distance between fluorescent pairs at which energy transfer is 50% efficient (i.e., at which 50% of excited donors are deactivated by FRET). The magnitude of Ro is dependent on the spectral properties of donor and acceptor dyes: Ro=[8.8×1023·K2·n−4·QYD·J(λ)]1/6 Å; where K2=dipole orientation range factor (
range 0 to 4, K2=⅔ for randomly oriented donors and acceptors).; QYD=fluorescence quantum yield of the donor in the absence of the acceptor; n=refractive index; and J( )=spectral overlap integral=∫εA(λ)·FD·(λ4)dλ cm3M−1, where εA=extinction coefficient of acceptor and FD=fluorescence emission intensity of donor as a fraction of total integrated intensity. Some typical Ro are listed for typical donor acceptor pairs in Table 1:TABLE 1 Donor Acceptor Ro (Å) Fluorescein Tetramethylrhodamine 55 IAEDANS Fluorescein 46 EDANS DABCYL 33 BODIPY FL BODIPY FL 57 Fluorescein QSY-7 dye 61 - An extensive compilation of Ro values are found in the literature; see Haugland (1996), supra. In most uses, the donor and acceptor dyes are different, in which case FRET can be detected by the appearance of sensitized fluorescence of the acceptor or by quenching of the donor fluorescence. When the donor and acceptor are the same, FRET is detected by the resulting fluorescence depolarization.
- In addition to quenching between fluorophores, individual fluorophores are also quenched by nitroxide-labeled molecules such as fatty acids. Spin labels such as nitroxides are also useful in the liquid phase assays of the invention.
- Test compounds and a polypeptide that includes an FXR ligand binding domain can be labeled with FRET pairs. If the test compound can directly interact with the FXR ligand binding domain, fluorescence resonance energy transfer can take place and the affinity can be measured. Alternatively, a known FXR ligand can be labeled with an appropriate FRET label and incubated with an FRET fluorophore labeled polypeptide that includes an FXR ligand binding domain. Fluorescence resonance energy transfer can take place between the labeled FXR ligand and the labeled FXR ligand binding domain. If a test compound were incubated with the two labeled components, the amount of FRET would be lowered if the test compound can inhibit or displace the binding of the labeled FXR ligand to the FXR ligand binding domain.
- Additional methods for assaying the ability of test compounds to modulate FXR interactions with its ligands employ peptide sensors. These assays can be adapted from those described in WO 99/27365. Briefly, these assays use a peptide sensor to which is attached a detectable label. The peptides are based on corepressor or coactivator protein motif sequences, either naturally occurring or derived from mutational analysis. The peptide sensors are derived from corepressors or coactivators that interact with FXR (e.g., a p160 coactivator, RXR, CPF, and others that are identified as described herein). Alternatively, the peptides can be obtained through randomizing residues and selecting for binding to the FXR receptor polypeptide. Panels of predetermined or randomized candidate sensors can be screened for receptor binding. For FXR peptide sensor assays, an example of a suitable peptide sensor is derived from the receptor-interacting domain of the coactivator SRC-1. This domain has been mapped to a short motif with the amino acid sequence LXXLL, where L is leucine and X is any amino acid. Fragments of SRC-1 or short synthetic peptides containing one LXXLL motif or more bind nuclear receptors in a ligand-dependent manner (Darimont et al. (1998)Genes Dev. 12: 3343; McInerney et al. (1998) Genes Dev. 12: 3357).
- In typical embodiments, the sensor peptides are labeled with a detectable label. The detectable labels can be primary labels (where the label comprises an element that is detected directly or that produces a directly detectable element) or secondary labels (where the detected label binds to a primary label, as is common in immunological labeling). An introduction to labels, labeling procedures and detection of labels is found in Polak and Van Noorden (1997)Introduction to Immunocytochemistry, 2nd ed., Springer Verlag, N.Y. and in Haugland (1996) Handbook of Fluorescent Probes and Research Chemicals, a combined handbook and catalogue published by Molecular Probes, Inc., Eugene, Oreg. Primary and secondary labels can include undetected elements as well as detected elements. Useful primary and secondary labels in the present invention can include spectral labels such as fluorescent dyes (e.g., fluorescein and derivatives such as fluorescein isothiocyanate (FITC) and Oregon Green™, rhodamine and derivatives (e.g., Texas red, tetrarhodimine isothiocynate (TRITC), etc.), digoxigenin, biotin, phycoerythrin, AMCA, CyDyes™, and the like), radiolabels (e.g., 3H, 125I, 35S, 14C, 32P, 33P, etc.), enzymes (e.g., horse radish peroxidase, alkaline phosphatase etc.), spectral colorimetric labels such as colloidal gold or colored glass or plastic (e.g., polystyrene, polypropylene, latex, etc.) beads. The label may be coupled directly or indirectly to a component of the detection assay (e.g., the detection reagent) according to methods well known in the art. As indicated above, a wide variety of labels may be used, with the choice of label depending on sensitivity required, ease of conjugation with the compound, stability requirements, available instrumentation, and disposal provisions. In a presently preferred embodiment, the detectable label is a fluorescent label, in which case fluorescence polarization detection provides a sensitive and efficient means of detecting whether the peptide sensor is bound to the FXR receptor polypeptide. See, e.g., Schindler et al. (1995) Immunity 2: 689-697).
- The sensor peptide and the FXR polypeptide are incubated under conditions that are suitable for sensor binding to the receptor polypeptide. In some embodiments, a candidate modulator of FXR binding to a corepressor, coactivator or other ligand is included in the reaction mixture. If a candidate modulator increases or decreases binding of the sensor peptide to the FXR polypeptide, the candidate modulator is a potential lead compound for blocking the FXR-mediated effect on transcription.
- 2. Cell-Based Screening Methods
- The present invention also provides cell-based methods for screening to identify compounds that are suitable for use as cholesterol level-mediating therapeutic agents, or that are suitable to further screening compounds that exhibit activity in the polypeptide-based assays described above. These methods provide an assay to determine whether expression of a gene involved in cholesterol hemostasis is affected by administration of the test compound.
- In some embodiments, these screening methods of the invention use a cell that contains a polypeptide that has a ligand binding domain (LBD) which is at least substantially identical to that of an FXR. The polypeptide typically will also include a DNA binding domain (DBD). The DBD can be substantially identical to that of an FXR (i.e., a full-length FXR is used), or to that of a receptor other than FXR for which the response element is known (e.g., GAL4, nuclear hormone receptors, and the like). Examples of suitable chimeric polypeptides are described in more detail below. Conveniently, the chimeric receptor polypeptide is introduced into the cell by expression of a polynucleotide that encodes the receptor polypeptide. For example, an expression vector that encodes the chimeric receptor can be introduced into the cell that is to be used in the assay. Suitable FXR polypeptides and chimeric receptors are described below.
- The cells will also contain a response element that can be bound by the DNA binding domain. Response elements, including glucocorticoid response elements (GRE) and estrogen response elements (ERE), are described in, for example, Jantzen et al. (1987)Cell 49: 29; Martinez et al. (1987) EMBO J. 6: 3719 and Burch et al. (1988) Mol. Cell. Biol. 8: 1123. Many other response elements are known; a commonly used response element is the GAL4 upstream activating sequence (UASG) (Keegan et al. (1986) Science 14: 699-704), which is responsive to binding by chimeric receptors that include the GAL4 DNA binding domain.
- The response element that is bound by the DNA binding domain used in the chimeric polypeptide is generally used in a reporter gene construct. In such constructs, the response element is operably linked to a promoter that is active in the cell. In presently preferred embodiments, the promoter is operably linked to a reporter gene that, when expressed, produces a readily detectable product. The response element/reporter gene construct is conveniently introduced into cells as part of a “reporter plasmid.”
- Suitable promoters include those described above. In presently preferred embodiments, the promoter is operably linked to a reporter gene that, when expressed, produces a readily detectable product. A variety of reporter gene plasmid systems are known, such as the chloramphenicol acetyltransferase (CAT) and β-galactosidase (e.g., bacterial lacZ gene) reporter systems, the firefly luciferase gene (See, e.g., Cara et al. (1996)J. Biol. Chem., 271: 5393-5397), the green fluorescence protein (see, e.g., Chalfie et al. (1994) Science 263:802) and many others. Examples of reporter plasmids are also described in U.S. Pat. No. 5,071,773. Selectable markers which facilitate cloning of the vectors of the invention are optionally included. Sambrook and Ausubel, both supra, provide an overview of selectable markers.
- In some embodiments of this assay, the reporter plasmid and an expression plasmid that directs expression of the chimeric receptor are introduced into a suitable host cell. Standard transfection methods can be used to introduce the vectors into the host cells. For mammalian host cells, preferred transfection methods include, for example, calcium phosphate precipitation (Chen and Okayama (1988)BioTechniques 6: 632), DEAE-dextran, and cationic lipid-mediated transfection (e.g., Lipofectin) (see, e.g., Ausubel, supra.). In some cases, the host cell, prior to introduction of the expression plasmid, should not contain an FXR receptor. See, e.g., U.S. Pat. No. 5,071,773 for suitable host cells for use in the assays.
- The assay methods involve contacting test cells that contain the reporter plasmid, the native or chimeric FXR polypeptide, and a ligand (e.g., bile acid) with the test compound. In some embodiments, an RXR polypeptide and/or other coactivators and corepressors which mediate the effect of FXR are also present in the test cells. For example, a cell that contains a reporter gene construct and the chimeric peptide can be grown in the presence and absence of putative modulatory compounds.
- The observed effect on reporter gene expression can depend on the particular assay system used. For example, when an FXR polypeptide that includes the FXR DBD, AF-2 domain, and LBD is used, cells grown in the absence of the FXR ligand will exhibit a level of reporter gene expression that is above the level observed in the absence of the ligand. Conversely, when a GAL4 DBD is used, binding of the ligand to the fusion polypeptide will result in increased expression the reporter gene to which is linked the GAL4 response element. Therefore, reporter gene expression is increased when cells are grown in the presence of a ligand for the FXR.
- B. FXR Polypeptides and Fusion Polypeptides
- The assays of the invention typically employ an FXR polypeptide. The FXR polypeptide can be a full-length FXR, or can include one or more domains of FXR. In some embodiments, one or more FXR domains (e.g., a DNA binding domain (DBD) or a ligand binding domain (LBD)) are used as a fusion protein with a domain from another polypeptide, such as another receptor. For example, some assay formats use a fusion protein that includes an FXR LBD fused to a DBD of another receptor.
- The FXR polypeptides and fusion polypeptides used in the assays of the invention can be made by methods known to those of skill in the art. For example, the FXR proteins or subsequences thereof can be synthesized using recombinant DNA methodology. Generally this involves creating a DNA sequence that encodes the polypeptide, modified as desired, placing the DNA in an expression cassette under the control of a particular promoter, expressing the protein in a host, isolating the expressed protein and, if required, renaturing the protein.
- FXR polypeptides, and polynucleotides that encode FXR polypeptides, are known to those of skill in the art. For example, cDNA sequences of FXR polypeptides from human (U68233),Branchiostoma lanceolatum (U93409), Danio rerio (zebrafish) (U93467), and rat (U18374) are found in GenBank. The nucleic acids that encode FXR can be used to express the FXR polypeptide, or to construct genes that encode a desired fusion polypeptide.
- FXR-encoding nucleic acids can be isolated by cloning or amplification by in vitro methods, such as the polymerase chain reaction (PCR), the ligase chain reaction (LCR), the transcription-based amplification system (TAS), the self-sustained sequence replication system (SSR). A wide variety of cloning and in vitro amplification methodologies are well-known to persons of skill. Examples of these techniques and instructions sufficient to direct persons of skill through many cloning exercises are found in Berger, Sambrook, and Ausubel (all supra.); Cashion et al., U.S. Pat. No. 5,017,478; and Carr, European Patent No. 0,246,864. Examples of techniques sufficient to direct persons of skill through in vitro amplification methods are found in Berger, Sambrook, and Ausubel, as well as Mullis et al. (1987) U.S. Pat. No. 4,683,202; PCR Protocols A Guide to Methods and Applications (Innis et al., eds) Academic Press Inc. San Diego, Calif. (1990) (Innis); Arnheim & Levinson (Oct. 1, 1990) C&EN 36-47; The Journal Of NIH Research (1991) 3: 81-94; (Kwoh et al. (1989) Proc. Nat'l Acad. Sci. USA 86: 1173; Guatelli et al. (1990) Proc. Natl. Acad. Sci. USA 87: 1874; Lomell et al. (1989) J. Clin. Chem. 35: 1826; Landegren et al. (1988) Science 241: 1077-1080; Van Brunt (1990) Biotechnology 8: 291-294; Wu and Wallace (1989) Gene, 4: 560; and Barringer et al. (1990) Gene 89: 117.
- In one preferred embodiment, FXR cDNAs can be isolated by routine cloning methods. The cDNA sequence provided in GenBank, for example, can be used to provide probes that specifically hybridize to a FXR gene in a genomic DNA sample, to an FXR mRNA in a total RNA sample, or to a FXR cDNA in a cDNA library (e.g., in a Southern or Northern blot). Once the target FXR nucleic acid is identified, it can be isolated according to standard methods known to those of skill in the art (see, e.g., Berger and Kimmel,Guide to Molecular Cloning Techniques, Methods in Enzymology 152 Academic Press, Inc., San Diego, Calif. (Berger); Sambrook et al. (1989) Molecular Cloning—A Laboratory Manual (2nd ed.) Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor Press, NY, (Sambrook et al.); Current Protocols in Molecular Biology, F. M. Ausubel et al., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (1994 Supplement) (Ausubel). In another preferred embodiment, the FXR nucleic acids can be isolated by amplification methods such as polymerase chain reaction (PCR).
- A polynucleotide that encodes an FXR polypeptide or fusion protein can be operably linked to appropriate expression control sequences for a particular host cell in which the polypeptide is to be expressed. ForE. coli, appropriate control sequences include a promoter such as the T7, trp, or lambda promoters, a ribosome binding site and preferably a transcription termination signal. For eukaryotic cells, the control sequences typically include a promoter which optionally includes an enhancer derived from immunoglobulin genes, SV40, cytomegalovirus, etc., and a polyadenylation sequence, and may include splice donor and acceptor sequences. In yeast, convenient promoters include GAL1,10 (Johnson and Davies (1984) Mol. Cell. Biol. 4:1440-1448) ADH2 (Russell et al. (1983) J. Biol. Chem. 258:2674-2682), PHO5 (EMBO J. (1982) 6:675-680), and MFα1 (Herskowitz and Oshima (1982) in The Molecular Biology of the Yeast Saccharomyces (eds. Strathem, Jones, and Broach) Cold Spring Harbor Lab., Cold Spring Harbor, N.Y., pp. 181-209).
- Expression cassettes are typically introduced into a vector which facilitates entry into a host cell, and maintenance of the expression cassette in the host cell. Vectors that include a polynucleotide that encodes an FXR polypeptide are provided by the invention. Such vectors often include an expression cassette that can drive expression of the FXR polypeptide. To easily obtain a vector of the invention, one can clone a polynucleotide that encodes the FXR polypeptide into a commercially or commonly available vector. A variety of common vectors suitable for this purpose are well known in the art. For cloning in bacteria, common vectors include pBR322 derived vectors such as pBLUESCRIPT™, and k-phage derived vectors. In yeast, vectors include Yeast Integrating plasmids (e.g., YIp5) and Yeast Replicating plasmids (the YRp series plasmids) and pGPD-2. A multicopy plasmid with selective markers such as Leu-2, URA-3, Trp-1, and His-3 is also commonly used. A number of yeast expression plasmids such as YEp6, YEp13, YEp4 can be used as expression vectors. The above-mentioned plasmids have been fully described in the literature (Botstein et al. (1979)Gene 8:17-24; Broach et al. (1979) Gene, 8:121-133). For a discussion of yeast expression plasmids, see, e.g., Parents, B., YEAST (1985), and Ausubel, Sambrook, and Berger, all supra). Expression in mammalian cells can be achieved using a variety of commonly available plasmids!, including pSV2, pBC12BI, and p91023, as well as lytic virus vectors (e.g., vaccinia virus, adenovirus, and baculovirus), episomal virus vectors (e.g., bovine papillomavirus), and retroviral vectors (e.g., murine retroviruses).
- FXR polypeptides and fusion polypeptides that include at least one FXR domain can be expressed in a variety of host cells, includingE. coli, other bacterial hosts, yeasts, filamentous fungi, and various higher eukaryotic cells such as the COS, CHO and HeLa cells lines and myeloma cell lines. Techniques for gene expression in microorganisms are described in, for example, Smith, Gene Expression in Recombinant Microorganisms (Bioprocess Technology, Vol. 22), Marcel Dekker, 1994. Examples of bacteria that are useful for expression include, but are not limited to, Escherichia, Enterobacter, Azotobacter, Erwinia, Bacillus, Pseudomonas, Klebsielia, Proteus, Salmonella, Serratia, Shigella, Rhizobia, Vitreoscilla, and Paracoccus. Filamentous fungi that are useful as expression hosts include, for example, the following genera: Aspergillus, Trichoderma, Neurospora, Penicillium, Cephalosporium, Achlya, Podospora, Mucor, Cochliobolus, and Pyricularia. See, e.g., U.S. Pat. No. 5,679,543 and Stahl and Tudzynski, Eds., Molecular Biology in Filamentous Fungi, John Wiley & Sons, 1992. Synthesis of heterologous proteins in yeast is well known and described in the literature. Methods in Yeast Genetics, Sherman, F., et al., Cold Spring Harbor Laboratory, (1982) is a well recognized work describing the various methods available to produce the enzymes in yeast.
- The nucleic acids that encode the polypeptides of the invention can be transferred into the chosen host cell by well-known methods such as calcium chloride transformation forE. coli and calcium phosphate treatment or electroporation for mammalian cells. Cells transformed by the plasmids can be selected by resistance to antibiotics conferred by genes contained on the plasmids, such as the amp, gpt, neo and hyg genes, among others. Techniques for transforming fungi are well known in the literature and have been described, for instance, by Beggs et al. ((1978) Proc. Nat'l. Acad. Sci. USA 75: 1929-1933), Yelton et al. ((1984) Proc. Natl. Acad. Sci. USA 81: 1740-1747), and Russell ((1983) Nature 301: 167-169). Procedures for transforming yeast are also well known (see, e.g., Beggs (1978) Nature (London), 275:104-109; and Hinnen et al. (1978) Proc. Natl. Acad. Sci. USA, 75:1929-1933. Transformation and infection methods for mammalian and other cells are described in Berger, Sambrook, and Ausubel, supra.
- Once expressed, the FXR polypeptides and/or fusion proteins can be purified, either partially or substantially to homogeneity, according to standard procedures of the art, such as, for example, ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis and the like (see, generally, R. Scopes,Protein Purification, Springer-Verlag, N.Y. (1982), Deutscher, Methods in Enzymology Vol. 182: Guide to Protein Purification., Academic Press, Inc. N.Y. (1990)). Once purified, partially or to homogeneity as desired, the polypeptides may then be used (e.g., in screening assays for modulators for gene expression or as immunogens for antibody production).
- One of skill in the art would recognize that after chemical synthesis, biological expression, or purification, the FXR polypeptides and/or fusion proteins may possess a conformation substantially different than the native conformations of the constituent polypeptides. In this case, it may be necessary to denature and reduce the polypeptide and then to cause the polypeptide to re-fold into the preferred conformation. Methods of reducing and denaturing proteins and inducing re-folding are well known to those of skill in the art (See, Debinski et al. (1993)J. Biol. Chem., 268: 14065-14070; Kreitman and Pastan (1993) Bioconjug. Chem., 4: 581-585; and Buchner, et al., (1992) Anal. Biochem., 205: 263-270). Debinski et al., for example, describe the denaturation and reduction of inclusion body proteins in guanidine-DTE. The protein is then refolded in a redox buffer containing oxidized glutathione and L-arginine.
- One of skill also would recognize that some modifications can be made to the FXR polypeptides without diminishing their biological activity. Such modifications can be made to facilitate the cloning, expression, or incorporation of the polypeptide into a fusion protein. Such modifications are well known to those of skill in the art and include, for example, a methionine added at the amino terminus to provide an initiation site, or additional amino acids (e.g., poly His) placed on either terminus to create conveniently located restriction sites or termination codons or purification sequences.
- C. Chimeric FXR Polypeptides
- The assays of the invention sometimes employ a chimeric FXR polypeptide that has at least a ligand binding domain and a DNA binding domain. At least one of the ligand binding domain and the DNA binding domain of the chimeric receptors of the invention is substantially identical to the corresponding domain of an FXR. These chimeric receptors are useful for many purposes. For example, one can use the chimeric receptors to identify additional ligands for the FXR and to identify response elements that are responsive to FXR. The chimeric receptors are also useful in screening assays for identifying compounds that can modulate interactions between FXR and its ligands and/or response elements.
- 1. DNA Binding Domains.
- The chimeric receptors used in the assays of the invention include those having a ligand binding domain that is at least substantially identical to a ligand binding domain of an FXR, as well as those that have a DNA binding domain that is not substantially identical to a DNA binding domain of an FXR. For example, the DNA binding domain binding domain can be about 90% or less identical to that of an FXR, more preferably about 75% or less, and most preferably about 60% or less identical. Often, the DNA binding domain is derived from a receptor other than a FXR. In a typical embodiment, the DNA binding domain is at least substantially identical to a DNA binding domain from a nuclear hormone receptor or a steroid hormone receptor.
- The modular nature of transcription regulators facilitates the construction of chimeric receptors that have domains that are derived from different receptors (Green and Chambon (1986)Nature 324: 615-617). For example, DNA binding domains derived from steroid, thyroid, and retinoid hormone receptor are suitable for use in the chimeric receptors of the invention. The DNA binding domains of receptors for steroid, thyroid, and retinoid hormones typically include two zinc finger units (Rhodes and Klug (February 1993) Scientific American, pp. 56-65). The DNA binding domains of these receptors, are generally cysteine-rich regions of about 65 amino acids that fold into two cysteine-rich “C4” type zinc fingers. The boundaries for many DNA binding domains have been identified and characterized for the steroid hormone superfamily. See, e.g., Giguere et al. (1986) Cell 46:645-652; Hollenberg et al. (1987) Cell 49:39-46; Green and Chambon (1987) Nature 325:74-78; Miesfield et al. (1987) Science 236:423-427; and Evans (1988) Science 240:889-895.
- Examples of receptors from which one can derive DNA binding domains that are suitable for use in the chimeric receptors of the invention include, for example, androgen receptors, estrogen receptors, glucocorticoid receptors, mineralcorticoid receptors, progesterone receptors, retinoic acid receptors (including α, β (hap), and γ), thyroid hormone receptors (including α and β), the gene product of the avian erythroblastosis virus oncogene v-erbA (which is derived from a cellular thyroid hormone receptor), vitamin D3 receptor, Drosophila ecdysone receptor (EcR), COUP transcription factor (also known as ear3) and its Drosophila homolog 7UP (svp), hepatocyte nuclear factor 4 (HNF-4), Ad4BP, apolipoprotein AI regulatory protein-1 (ARP-1), peroxisome proliferator activated receptor (PPAR), Drosophila protein knirps (kni), Drosophila protein ultraspiracle (usp; chorion factor 1), human estrogen receptor related genes 1 and 2 (err1 and err2), human erbB related gene 2 (ear2), human NAK1/mouse nur/77 (N10)/rat NGFI-B; Drosophila protein embryonic gonad (egon), Drosophila knirps-related protein (knr1), Drosophila protein tailless (tll), Drosophila 20-O-ecdysone regulated protein E75, and Drosophila Dhr3. Some of these and other suitable receptors are described in, for example, Evans, RM (1988)Science 240: 889-895; Gehrig, U. (1987) Trends Biochem. Sci. 12: 399-402; Beato, M. (1989) Cell 56: 335-344; Laudet et al. (1992) EMBO J. 11: 1003-1013.
- In some embodiments, the chimeric receptors include a DNA binding domain from a DNA-binding polypeptide other than a nuclear receptor. For example, chimeric receptors that have the DNA binding domain of GAL4, which is a positive regulatory protein of yeast (Giniger et al. (1985)Cell 40: 767-774; Sadowski et al. (1992) Gene 118: 137-141) linked to a ligand binding domain of an FXR polypeptide are provided. GAL4 DNA binding domain-containing fusion proteins can be readily expressed by cloning a coding sequence for an FXR ligand binding domain into a commercially available expression vector that includes a GAL4 DNA binding domain coding sequence under the control of a promoter (e.g., pAS2-1 (CLONTECH Laboratories, Inc.). Another example of a well-characterized DNA binding domain for which expression vectors are commercially available is that of LexA (pLexA, CLONTECH). The chimeric receptors can also include a nuclear localization sequence associated with the DNA binding domain (see, e.g., Silver et al. (1984) Proc. Nat'l. Acad. Sci. USA 81: 5951-5955 for a GAL4 nuclear localization sequence).
- The chimeric receptors can use an entire receptor molecule as a DNA binding domain, or can use portions of molecules that are capable of binding to nucleic acids, directly or indirectly. To identify such DNA binding domains, one can perform assays such as an electrophoretic mobility shift assay (EMSA) (Scott et al. (1994)J. Biol. Chem. 269: 19848-19858), in which a nucleic acid of interest is allowed to associate with various fragments of a polypeptide to identify those fragments that are capable of binding to the nucleic acid. Association of a portion of the protein with the nucleic acid will result in a retardation of the electrophoretic mobility of the nucleic acid. Another method by which one can identify DNA binding moieties that are suitable for use as DNA binding domains is DNase I footprinting, which is well known to those of skill in the art.
- The DNA binding domain can be either a polypeptide or a nucleic acid. Where the DNA binding domain is a nucleic acid, the nucleic acid will be capable of specifically hybridizing to a target nucleic acid site, such as a response element. Hybridization of the nucleic acid to the target site will place the chimeric receptor in a position suitable for activating or repressing expression of a gene that is linked to the target site. An example of an oligonucleotide being chemically linked to a protein by chemical coupling is found in Corey et al. (1989)Biochemistry 28: 8277-8286.
- These chimeric receptors are useful, for example, in assays to identify modulators of FXR transcriptional regulation activity as described below.
- 2. Ligand Binding Domains.
- The assays of the invention typically use chimeric or non-chimeric FXR receptors in which the ligand binding domain is at least substantially identical to a ligand binding domain of an FXR polypeptide.
- 3. Production of Chimeric FXR Receptors
- To form a chimeric receptor for use in the assay of the invention, the ligand binding domain and the DNA binding domain are linked together. Suitable methods of forming such linkages are known to those of skill in the art. For a review of methods for constructing fusion proteins between receptor ligand binding domains and DNA binding domains, see, e.g., Mattioni et al. (1994)Methods in Cell Biology 43(Pt A): 335-352. The linkage can be done using either recombinant or chemical methods. For example, a cysteine residue can be placed at either end of a domain so that the domain can be linked to another domain by, for example, a sulfide linkage. More typically, the ligand binding domains and DNA binding domains are joined by linkers, which are typically polypeptide sequences, such as poly glycine sequences of between about 5 and 200 amino acids, with between about 10-100 amino acids being typical. In some embodiments, proline residues are incorporated into the linker to prevent the formation of significant secondary structural elements by the linker. Preferred linkers are often flexible amino acid subsequences which are synthesized as part of a recombinant fusion protein. In one embodiment, the flexible linker is an amino acid subsequence comprising a proline such as Gly(x)-Pro-Gly(x) where x is a number between about 3 and about 100. A linker can also be a single peptide bond, or one or more amino acid residues. In other embodiments, a chemical linker is used to connect synthetically or recombinantly produced ligand binding domain and DNA binding domain subsequences. Such flexible linkers are known to persons of skill in the art. For example, poly(ethylene glycol) linkers are available from Shearwater Polymers, Inc. Huntsville, Ala. These linkers optionally have amide linkages, sulfhydryl linkages, or heterofunctional linkages.
- The chimeric receptors are conveniently produced by recombinant expression in a host cell. Accordingly, the invention provides chimeric nucleic acids that encode a fusion protein that includes a DNA binding domain and a ligand binding domain, at least one of which is at least substantially identical to the corresponding domain of an FXR of the invention. In some embodiments, the chimeric nucleic acid will also encode a linker region that provides a link between the two domains. Techniques for making such chimeric nucleic acids are known to those of skilled in the art. For example, recombinant methods can be used (see, e.g., Berger and Sambrook, both supra.). Alternatively, the nucleic acid encoding the chimeric receptors can be synthesized chemically.
- To obtain expression of a chimeric receptor, a nucleic acid that encodes the chimeric receptor is generally placed under the control of a promoter and other control elements that can drive expression of the chimeric gene in a desired host cell. Accordingly, the invention also provides expression cassettes in which a promoter and/or other control elements are operably linked to a polynucleotide that encodes a chimeric receptor. Suitable promoters, other control sequences, and expression vectors are described above.
- D. Assays for FXR Ligands and Response Elements
- Also provided by the invention are methods for identifying corepressors, coactivators, and additional ligands that interact with FXR. Also provided are methods of identifying response elements that are mediated by transcription complexes that include FXR. These components are useful in the screening assays of the invention.
- 1. Identification of Ligands for FXR
- Many of the screening assays of the invention utilize ligands for FXR. Accordingly, the invention provides methods for identifying additional ligands for FXR. The identification of previously unknown FXR ligands is of particular interest not only for the knowledge obtained regarding the regulation of cholesterol metabolism, but also for identifying new compounds that can modulate FXR-mediated regulation of genes that are involved in cholesterol metabolism.
- Candidate ligands include not only bile acids and related compounds, but also transcription factors, coactivators, and corepressors with which FXR might interact. These potential ligands can include other receptor polypeptides (e.g., RXR, coactivators, and the like), which comprise the cellular machinery for regulation of gene expression. For example, nuclear hormone receptors often interact with transcriptional coactivators. Thus, the invention also provides methods of identifying coactivators, corepressors and other molecules that interact with FXRs. These assay methods can involve introducing a coactivator or a corepressor that is a candidate ligand for FXR into a host cell that contains a chimeric FXR and reporter plasmid. The coactivator can be introduced by means of an expression construct; this expression construct can be present on the same or a different vector than the expression construct for the chimeric receptor.
- Ligands for FXR can be identified using the methods described above for screening to identify compounds that modulate FXR interactions with the ligands. Instead of including a compound that potentially modulates the interaction, the assays are conducted using a potential FXR ligand. Both polypeptide-based and cell-based assays can be used.
- 2. Identification of Response Elements for Transcription Complexes that Include FXR
- The present invention provides methods for obtaining response elements that are responsive to transcription complexes that include FXR. Through use of such methods, one can identify additional genes for which expression is modulated by the FXRs. The methods typically involve contacting a putative response element with a polypeptide that includes a FXR DNA binding domain (see, e.g., Ausubel et al., supra.). Both cell-based and biochemical methods are provided. In presently preferred embodiments of the assays for identification of FXR response elements, a FXR receptor, or FXR DNA binding domain is used. The ligand binding domain is preferably one for which an appropriate ligand is available. Suitable chimeric receptors are described above.
- Also provided are methods of identifying response elements to which FXR does not directly bind. For example, FXR can form a transcription regulatory complex with one or more other coactivators and/or corepressors. One or more of these other molecules can actually bind to the response element. For example, FXR can bind to CPF, which in turn binds to a response element located upstream of the cyp7a gene.
- In some embodiments, standard gel shift assays are performed to identify polynucleotides that can bind to a FXR DNA binding domain. These assays are performed by incubating a polypeptide that includes a FXR DNA binding domain, either as a purified protein or a complex mixture of proteins) with a labeled DNA fragment that contains the putative FXR binding site. Reaction products are analyzed on a nondenaturing polyacrylamide gel. To determine the specificity of the binding, one can perform competition experiments using polynucleotides that include a FXR binding site, or unrelated DNA sequences. Kits for performing gel shift assay include, for example, Gel Shift Assay Systems (Promega, Madison Wis., Part No. TB110).
- Another in vitro assay for identifying FXR response elements is the binding site selection method (see, e.g., U.S. Pat. No. 5,582,981). In this method, a library of oligonucleotides having a randomized nucleotide sequence of about 18 nucleotides flanked by two known nucleotide sequences of sufficient length to allow hybridization to PCR primers that are complementary to these regions. The oligonucleotides are end-labeled (e.g., with γ-32P) and contacted with a FXR DNA binding domain polypeptide. A low stringency gel shift experiment is performed. PCR amplification is then carried out on those oligonucleotides to which the FXR DNA binding domain bound, as evidenced by retardation in the gel shift electrophoresis. Preferably, the selection and amplification process is repeated at least twice more using the amplified fragments.
- In vivo assays for FXR response elements are also provided. The in vivo assays are particularly suitable for confirming results obtained in an in vitro assay. Cells are provided which contain a reporter construct that contains the putative response element in a position relative to a promoter at which binding of an FXR polypeptide can increase or decrease expression of an operably linked gene. The putative response element can be, for example, a member of a library of polynucleotide fragments. The chimeric receptor and the reporter constructs are introduced into a host cell. Suitable host cells are described in, for example, U.S. Pat. No. 5,071,773. The host cells that contain the reporter plasmid construct and the chimeric receptor are grown in the presence of the ligand for the ligand binding domain used in the chimeric receptor. Those cells in which expression of the reporter gene in the presence of the ligand is greater or less than the expression in the absence of the ligand contain a reporter construct that includes a putative response element for an FXR. The response elements can be isolated from these cells by, for example, plasmid recovery, PCR amplification, or other methods known to those of skill in the art. Upon isolation, the response elements can be characterized (e.g., by sequencing) and used to identify additional genes for which expression is influenced by FXRs.
- E. Compositions, Kits and Integrated Systems
- The invention provides compositions, kits and integrated systems for practicing the assays described herein. For example, the invention provides an assay system that includes an FXR polypeptide and a ligand for FXR. Also provided are assay systems for cell-based screening to identify FXR-modulating compounds. Such systems typically include an expression vector for a full-length or chimeric FXR polypeptide, a vector that contains an appropriate reporter gene under the control of a transcription complex that includes FXR, and a suitable host cell is provided by the present invention. Ligands that bind to the ligand binding domain of FXR can also be included in the assay compositions, as can modulators of FXR activity.
- The invention also provides kits for practicing the FXR assay methods noted above. The kits can include any of the compositions noted above, and optionally further include additional components such as written instructions to practice a high-throughput method of assaying for FXR activity, or screening for an inhibitor or activator of FXR activity, one or more containers or compartments (e.g., to hold reagents, nucleic acids, or the like), and a control FXR activity modulator.
- The invention also provides integrated systems for high-throughput screening of potential FXR modulators for an effect on binding of FXR to ligands for FXR. In other some systems, the modulation of expression of genes that are under the control of FXR, such as the cyp7a gene that modulates cholesterol metabolism, is tested. The systems typically include a robotic armature which transfers fluid from a source to a destination, a controller which controls the robotic armature, a label detector, a data storage unit which records label detection, and an assay component such as a microtiter dish comprising a well having a reaction mixture or a substrate.
- F. Pharmaceutical Compositions and Methods for Treating Cholesterol-related Disorders
- FXR-mediated disorders and conditions, such as atherosclerosis, cardiovascular disorders, lipid disorders and hypercholesterolemia, can be treated with therapeutic agent(s) identified using the methods described herein. The candidate therapeutic agent is typically prepared as a pharmaceutical composition and is administered to a subject suffering from a FXR-mediated disorder or condition. Preferably, the candidate therapeutic agents will, upon administration to the subject, cause total cholesterol levels to decrease about 10%, more preferably a decrease of about 20%, and most preferably a decrease of about 25-45%.
- 1. Pharmaceutical Compositions
- Accordingly, the present invention provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier or excipient and a candidate therapeutic agent. Pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
- In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
- The powders and tablets preferably contain from 5% or 10% to 70% of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term “preparation” is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
- For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
- Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
- Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents as desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
- Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
- The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
- The quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 1000 mg, preferably 1.0 mg to 100 mg according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents.
- 2. Treatment Regime Using Candidate Therapeutic Agents
- The present invention also provides methods of modulating FXR activity in a cell. In this aspect, a cell is contacted with an FXR-modulating amount of a compound or composition above. An FXR-modulating amount can be readily determined using the assays described briefly above, or alternatively, using the assays in the Examples below. Candidate therapeutic agents are especially useful in the treatment of hypercholesterolemia.
- In another aspect, the present invention provides methods of treating conditions modulated by FXR in a host animal, by administering to the host an effective amount of a compound or composition provided above. In therapeutic applications, the compounds of the present invention can be prepared and administered in a wide variety of oral and parenteral dosage forms. Thus, the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, the compounds described herein can be administered by inhalation, for example, intranasally. Additionally, the compounds of the present invention can be administered transdermally.
- A variety of conditions are modulated, at least in part, by FXR, including hypercholesterolemia or other conditions associated with abnormal cholesterol or lipid homeostasis such as atherosclerosis, lipid disorders and cardiovascular disorders. The compounds utilized in the pharmaceutical method of the invention are administered at the initial dosage of about 0.001 mg/kg to about 100 mg/kg daily. A daily dose range of about 0.1 mg/kg to about 10 mg/kg is preferred. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.
- Typically, the host or subject in each of these methods is human, although other animals can also benefit from the foregoing treatments.
- The following examples are offered to illustrate, but not to limit the present invention. Some of these experiments are described in Makishima et al. (1999)Science 284: 1362-1365, which was published after the priority date of the instant application.
- This Example demonstrates that the primary bile acid chenodeoxycholic acid (CDCA) specifically activates the gene expression regulatory activity of FXR. The experiment was conducted using fusion polypeptides in which a ligand binding domain of FXR and other nuclear receptors were independently linked to the DNA binding domain (DBD) of Gal4. These in-frame fusions of the Gal4 DNA-binding domain (Gal4 DBD, pM3 expression vector) and the ligand-binding domains (LBDs) of FXR, HNF4α, LXRα, RXRα and LXRβ nuclear receptors were used to determine the specificity of FXR transactivation by chenodeoxycholic acid (CDCA).
- HepG2 cells were transiently transfected with a reporter plasmid in which a luciferase-encoding gene was under the control of a pGL3 5× GAL4 response element (which consists of five GAL4 binding elements) (0.25 μg/1.5×105 cells). The cells were also transfected with the empty expression vector pM3 or the pM3-LBD fusion expression plasmids (0.25 μg/1.5×105 cells) as indicated. Luciferase reporter activity was measured after treating cells with or without 50 μM CDCA. For each fusion plasmid, fold activation is a ratio of luciferase activity (normalized by β-galactosidase activity) between treated and untreated cells. The FXR fusion construct was the sole receptor transactivated by CDCA (see, FIG. 1A).
- This example further illustrates that CDCA-mediated transactivation of FXR is dose-dependent. HepG2 cells were transiently transfected with the pGL3 3× FXRE (three FXR response elements, AGGTCAATGACCT) luciferase reporter plasmid (0.25 μg/1.5×105 cells), plus empty expression vector (pcDNA3) or a plasmid expressing full-length FXR (pFXR) (0.15 μg/1.5×105 cells). Luciferase reporter activity was measured after treating cells with or without CDCA (concentrations as indicated). Fold activation was calculated as the ratio of luciferase activity (normalized by β-galactosidase activity) between treated and untreated cells. A dose-dependent transactivation (
IC 50 10 μM CDCA) of the reporter gene by FXR was observed (see, FIG. 1B). - This example illustrates that CDCA-mediates FXR-specific suppression of CYP7 expression. Full-length nuclear receptors FXR, CPF, HNF4α, LXRα and RXRα were assayed to determine their ability to suppress CYP7 expression in the presence of 10 μM CDCA. In this experiment, a luciferase reporter plasmid under the control of the cyp7a promoter (−718 to +14, where +1 designates the transcriptional start site) (pGL3-CYP7) was used. HepG2 cells were transiently transfected with the pGL3-CYP7 luciferase reporter (0.25 μg/1.5×105 cells) plus empty expression vector (pcDNA3) or plasmids expressing one of the indicated nuclear receptors (0.25 μg/1.5×105 cells). Luciferase reporter activity was measured after treating cells with or without 10 μM CDCA. The ratio of luciferase activity (normalized by β-galactosidase activity) between treated and untreated pcDNA3-transfected cells was set at 100 percent CYP7 expression. The percent CYP7 expression for the nuclear receptors was normalized to that of pcDNA3. Only FXR suppressed CYP7 expression under these conditions (see, FIG. 2A).
- This example further illustrates the dose response profile of CDCA-mediated suppression of CYP7 expression by FXR. HepG2 cells were transiently transfected with the pGL3-CYP7 luciferase reporter plasmid (0.25 μg/1.5×105 cells), plus empty expression vector (pcDNA3) or a plasmid expressing full-length FXR (pFXR) (0.15 μg/1.5×105 cells). Luciferase reporter activity was measured after treating cells with or without CDCA (concentrations as indicated). The presence of FXR alone suppresses CYP7 expression, and this suppression is enhanced with the addition of CDCA (see, FIG. 2B).
- This example illustrates that CDCA-mediated FXR suppression is specific for CYP7. FXR does not suppress expression of the low density lipoprotein (LDL) receptor. This experiment was conducted using a second luciferase reporter plasmid, named p-6500, in which the luciferase gene is under the control of a 6.5 kilobase pair (kb) promoter region of the LDL receptor. HepG2 cells were transiently transfected with pGL3-CYP7 or p-6500. Cells were also transfected with either empty expression vector (pcDNA3) or a plasmid that expresses full-length FXR (pFXR) (all at 0.25 μg/1.5×105 cells). Luciferase reporter activity was measured after treating cells with or without 10 μM CDCA. The ratio of luciferase activity (normalized by β-galactosidase activity) between treated and untreated pcDNA3-transfected cells was set at 100 percent CYP7 expression. No FXR/CDCA-mediated suppression of the p-6500 reporter was observed (see, FIG. 3A).
- This example further illustrates that CYP7 suppression is lost upon titrating away FXR. HepG2 cells were transiently transfected with pGL3-CYP7 luciferase reporter plasmid (50 ng/1.5×105 cells), plus an empty expression vector (pcDNA3) or a plasmid expressing full-length FXR (pFXR) (0.25 μg/1.5×105 cells). Cells were also transfected with a competitor plasmid, either pBSKS or pGL3 3× FXRE Aluc (0.5 μg/1.5×105 cells). Luciferase reporter activity was measured after treating cells with or without 10 μM CDCA. For each competitor, the ratio of luciferase activity (normalized by β-galactosidase activity) between treated and untreated pcDNA3-transfected cells was set at 100 percent CYP7 expression. Loss of CYP7 suppression was observed when ten-fold excess pGL3 3× FXR Aluc was cotransfected with the CYP7 reporter gene (see, FIG. 3B). This result strongly suggests that FXR is a component of the bile acid-mediated suppression of CYP7.
- This example further illustrates that FXR mutants do not suppress CYP7 expression. FXR mutants were created and assayed to determine whether they are able to suppress CYP7 in a CDCA-dependent manner. HepG2 cells were transiently transfected with the pGL3-CYP7 luciferase reporter plasmid (0.25 μg/1.5×105 cells), plus empty expression vector (pcDNA3) or a plasmid expressing full-length wild-type FXR (pFXR) or mutant (DNA-binding domain [DBD], ligand-binding domain [pLBD], and AF2 domain truncation [dAF2]) FXR (0.25 μg/1.5×105 cells). Luciferase reporter activity was measured after treating cells with or without 10 μM CDCA. The ratio of luciferase activity (normalized by β-galactosidase activity) between treated and untreated pcDNA3-transfected cells was set at 100 percent CYP7 expression. None of the FXR derivatives had any effect upon CYP7 suppression (see, FIG. 3C).
- This example demonstrates that bile acids and FXR repress expression from the promoter for the cholesterol 7α-hydroxylase (Cyp7A) gene, which is the rate-limiting enzyme in cholesterol metabolism. Both the expression of Cyp7A protein and mRNA (FIG. 4A in a hepatocyte-derived cell line were analyzed. HepG2 cells were seeded at an initial density of 1×106 cells/well in a 6-well plate, and allowed to grow for approximately 24 hours at 37° C., 5% CO2 in DMEM-F12 medium (Mediatech) supplemented with 10% fetal calf serum. Once the cell culture became confluent, the medium was replaced with DMEM-F12 without serum, and supplemented with primary or conjugated bile acids at a final concentration of 50 μM. The cultures were then incubated at 37° C., 5% CO2 for 24 hours.
- An immunoblot analysis using an antibody to Cyp7a was performed on lysates from human HepG2 cells after treatment with bile acids. Quantitative RT-PCR analysis of CYP7A mRNA in HepG2 cells was performed as follows. Total RNA was prepared from HepG2 cells using Tri Reagent (Molecular Research Center, Inc.), according to the recommendations of the manufacturer. Following extraction with Tri Reagent and precipitation with ethanol, the RNA was resuspended in DEPC-treated water and stored at −80° C. prior to analysis. The following primers were used for amplification and analysis of human CYP7 mRNA by RT-PCR: CYP7−78: 5′-tgatttgggggattgctata-3′, CYP7−178: 5′-catacctgggctgtgctct-3′, and CYP7−132(FAM): 5′-(6-FAM)tggttcacccgtttgccttctcct(TAMRA)-3′. As a control, a primer set for detection of human GAPDH mRNA was used; this set is commercially available and was obtained from Applied Biosystems/Perkin Elmer, Inc.
- Amplification of specific target mRNAs was carried out by reverse transcription followed by polymerase chain reaction using the TaqMan One Step Gold RT-PCR Kit (Applied Biosystems/Perkin Elmer, Inc.). Each primer set included a pair of amplification primers and the fluorogenic probe primer as indicated, and were present in the reaction at a final concentration of 100 nM/primer. One μg of total RNA isolated from the various culture conditions was used as template in individual RT-PCR reactions.
- Analysis of GAPDH mRNA and CYP7A mRNA were carried out in triplicate in parallel reactions. Reactions were carried out using the ABI Prism 7700 Sequence Detector (Perkin Elmer, Inc.) Reverse transcription was allowed to proceed for 30 minutes at 48° C., followed by amplification of the cDNA by 40 cycles of PCR, each consisting of a melting step (95° C. for 15 seconds) and a combined annealing-extension step (60° C. for 1 minute). During PCR, the cycle-to-cycle changes in fluorescence due to template amplification were monitored, allowing the amount of amplified product to be determined, and the initial template concentration to be calculated. These values were used to compare the steady-state levels of accumulated CYP7A and GAPDH mRNA in HepG2 cells grown in the presence and absence of bile acids (see, FIG. 4A).
- Also examined was the effect of bile acids on coactivator recruitment to FXR. A mammalian two-hybrid assay was used to demonstrate that FXR interacts with the coactivator SRC-1. In this experiment, a plasmid expressing a GAL4 DNA-binding domain-SRC-1 fusion protein and a plasmid expressing an FXR ligand-binding domain-VP-16 fusion protein were used. HepG2 cells were transiently transfected with the pG5 luciferase reporter plasmid (a luciferase gene under the control of five GAL4 binding sites) (0.25 μg/1.5×105 cells) and the plasmids expressing the two fusion proteins. Luciferase reporter activity was measured after treating cells with or without the panel of bile acids (concentrations as indicated) (FIG. 4B). Relative luciferase activity is a ratio of luciferase activity (normalized by β-galactosidase activity) between treated and untreated cells.
- The ability of different bile acids and derivatives to activate FXR-mediated transactivation was also examined. HepG2 cells were transiently transfected with the pGL3 3× FXRE luciferase reporter plasmid (0.25 μg/1.5×105 cells) and a plasmid expressing full-length FXR (pFXR) (0.15 μg/1.5×105 cells). Luciferase reporter activity was measured after treating cells with or without the panel of bile acids (concentrations as indicated). Fold activation is a ratio of luciferase activity (normalized by β-galactosidase activity) of treated and untreated cells. Treatment with CDCA, followed by deoxycholic acid (DCA) and glycochenodeoxycholic acid (GCDCA), had the greatest induction of luciferase reporter activity (FIG. 4C).
- The effect of different bile acids and derivatives on FXR-mediated suppression of CYP7 expression was also studied. HepG2 cells were transiently transfected with the pGL3-CYP7 luciferase reporter plasmid (0.25 μg/1.5×105 cells) and a plasmid expressing full-length FXR (pFXR) (0.15 μg/1.5×105 cells). Luciferase reporter activity was measured after treating cells with or without the panel of bile acids (concentrations as indicated). Luciferase reporter activity for untreated cells was defined as 100% percent CYP7 expression. The highest level of suppression of CYP7 expression was observed with CDCA treatment followed by DCA (see, FIG. 4D).
- CDCA treatment resulted in the largest induction of luciferase activity (see, FIGS. 4B and 4C), and also the largest repression of CYP7a expression (FIG. 4D). The rank order of bile acids in these activity-measuring experiments was the same as that for repressing endogenous expression of human Cyp7a protein and mRNA (FIG. 4A)
- This Example describes three different high throughput in vitro assay that are useful for screening to identify compounds that can modulate binding of FXR ligands to the FXR ligand binding domain. The ability of different bile acids and derivatives to affect the binding of a labeled sensor peptide that is derived from the coactivator SRC-1 to an FXR ligand binding domain was tested.
- Fluorescence Polarization
- Fluorescence polarization was used to study the effect of different bile acids on the ability of the FXR LBD to bind a sensor peptide. The assay reagents were as follows:
- Reagents:
- Sensor: Rhodamine-labeled ILRKLLQE peptide (final conc.=1-5 nM). It is noted that the Rhodamine-labeled peptide comprises, at a minimum, the following sequence LXXLLXX, wherein X is any amino acid. Additional amino acids can be added to both the N-terminus and the C-terminus of this core peptide. In preferred embodiments, the peptide is 8 amino acids in length and, more preferable, about 11 amino acids in length.
- Receptor: Glutathione-S-transferase/FXR ligand binding domain fusion protein (final conc.=100-200 nM).
- Buffer: 10 mM HEPES, 10 mM NaCl, 6 mM magnesium chloride, pH 7.6
- Protocol:
- 1. Add 90 microliters of Sensor/Receptor mixture to each well of a 96-well microtiter plate.
- 2. Add 10 microliters of test compound per well.
- 3. Shake 5 minutes and within 5 minutes determine the amount of fluorescence polarization by using a Fluorolite FPM-2 Fluorescence Polarization Microtiter System (Dynatech Laboratories, Inc.
- Ten ng/μL of GST-FXR fusion protein was mixed with a rhodamine-labeled peptide comprising LXXLLXX, wherein X is any amino acid, and the panel of bile acids (concentrations as indicated). Fluorescence polarization was read after a room temperature incubation and brief shaking. Change in millipolarization (mP) units is the difference treated and untreated samples. The high change in mP units demonstrates that the labeled peptide binds to GST-FXR in a CDCA-dependent manner (see, FIG. 5A).
- Fluorescence Resonance Energy Transfer
- FIG. 5B shows the results of an experiment in which fluorescence resonance energy transfer (FRET; also referred to as HTRF) was used to study the effect of different bile acids on the ability of FXR to bind the coactivator SRC-1. The top panel shows that FXR-SRC-1 binding is stimulated by bile acids. The bottom panel of FIG. 5B shows that the binding of the LXRα receptor control is affected not by the bile acids, but rather by the
LXRα ligand - ELISA
- An enzyme-linked immunosorbent assay (ELISA) was used to study the effect of bile acids on ligand-induced conformational changes of FXR. A peptide sensor was used. The results, which are shown in FIG. 5C, demonstrate that increasing concentrations of bile acids (in particular, CDCA) result in an increase in the amount of peptide sensor that is bound to the FXR ligand binding domain. The binding of the sensor peptide to the LXRα control (bottom panel), in contrast, was not affected by the bile acids. Only the
LXRα ligand - From the foregoing examples, it is readily apparent that the orphan nuclear receptor FXR is involved in the bile acid-dependent suppression of the human cyp7 gene. The primary bile acid CDCA (chenodeoxycholic acid) specifically transactivates FXR and does so in a dose-dependent manner (IC50=10 M). Overexpression of FXR was found to suppress cyp7 expression and the suppression was enhanced in the presence of CDCA. This enhanced suppression is specifically mediated by FXR and seems to be specific to the cyp7 promoter. By using a panel of bile acids, it was demonstrated that the bile acid-mediated FXR activation correlates with bile acid-mediated human cyp7 suppression. Moreover, by using an in vitro biochemical peptide sensor assay and the cell-based mammalian two-hybrid assay, it was demonstrated that when FXR is bound by CDCA, the activated complex is able to recruit SRC-1 to the complex. In summary, the results strongly suggest that FXR functions as a bile acid receptor/sensor that mediates cyp7 expression in a bile-acid dependent manner.
- It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference for all purposes.
Claims (47)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/217,293 US20030003520A1 (en) | 1999-01-07 | 2002-08-12 | FXR receptor-mediated modulation of cholesterol metabolism |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11524999P | 1999-01-07 | 1999-01-07 | |
US09/478,948 US6465258B1 (en) | 1999-01-07 | 2000-01-06 | FXR receptor-mediated modulation cholesterol metabolism |
US10/217,293 US20030003520A1 (en) | 1999-01-07 | 2002-08-12 | FXR receptor-mediated modulation of cholesterol metabolism |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/478,948 Continuation US6465258B1 (en) | 1999-01-07 | 2000-01-06 | FXR receptor-mediated modulation cholesterol metabolism |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030003520A1 true US20030003520A1 (en) | 2003-01-02 |
Family
ID=22360168
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/478,948 Expired - Lifetime US6465258B1 (en) | 1999-01-07 | 2000-01-06 | FXR receptor-mediated modulation cholesterol metabolism |
US10/217,293 Abandoned US20030003520A1 (en) | 1999-01-07 | 2002-08-12 | FXR receptor-mediated modulation of cholesterol metabolism |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/478,948 Expired - Lifetime US6465258B1 (en) | 1999-01-07 | 2000-01-06 | FXR receptor-mediated modulation cholesterol metabolism |
Country Status (3)
Country | Link |
---|---|
US (2) | US6465258B1 (en) |
AU (1) | AU2409600A (en) |
WO (1) | WO2000040965A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060160111A1 (en) * | 2004-12-02 | 2006-07-20 | Vanderbilt University | Measuring forster resonance energy transfer with polarized and depolarized light |
WO2020243590A1 (en) | 2019-05-30 | 2020-12-03 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease |
US10894054B2 (en) | 2015-04-07 | 2021-01-19 | Intercept Pharmaceuticals, Inc. | FXR agonist compositions for combination therapy |
US11311557B2 (en) | 2015-02-06 | 2022-04-26 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions for combination therapy |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020028876A (en) * | 1999-04-30 | 2002-04-17 | 추후제출 | Steroid derivatives |
US6906057B1 (en) | 1999-06-11 | 2005-06-14 | Allergan, Inc. | Methods for modulating FXR receptor activity |
JP2003502337A (en) | 1999-06-11 | 2003-01-21 | アラーガン・セイルズ・インコーポレイテッド | Organosilyl compounds having nuclear hormone receptor modulating activity |
US7094559B1 (en) | 2000-08-08 | 2006-08-22 | Wyeth | Assay to identify estrogen receptor dependent ligands that regulate the hepatic lipase promoter |
FR2820435B1 (en) * | 2001-02-05 | 2004-02-27 | Genfit S A | METHODS OF IDENTIFYING COMPOUNDS MODULATING THE REVERSE TRANSPORT OF CHOLESTEROL |
WO2002062302A2 (en) * | 2001-02-08 | 2002-08-15 | The University Of Chicago | Steroidal derivatives |
US20020119958A1 (en) * | 2001-02-13 | 2002-08-29 | Shinichiro Tojo | Therapeutic agent for hyperlipidemia |
AU2002308295B2 (en) | 2001-03-12 | 2007-08-23 | Intercept Pharmaceuticals, Inc. | Steroids as agonists for FXR |
CN100360550C (en) * | 2001-05-03 | 2008-01-09 | 芝加哥大学 | Liver X receptor agonists |
US20070197484A1 (en) * | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
US7078396B2 (en) * | 2001-05-03 | 2006-07-18 | Arch Development Corporation | Method of treating disorder related to high cholesterol concentration |
US7053076B2 (en) | 2001-08-29 | 2006-05-30 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
US7998986B2 (en) | 2001-12-21 | 2011-08-16 | Exelixis Patent Company Llc | Modulators of LXR |
AU2002367060A1 (en) | 2001-12-21 | 2003-07-30 | X-Ceptor Therapeutics, Inc. | Heterocyclic modulators of nuclear receptors |
EP1353182A3 (en) * | 2002-04-12 | 2004-02-04 | Smithkline Beecham Corporation | Method of predicting cell-based assay results using binding profiles |
AU2003228485A1 (en) * | 2002-04-12 | 2003-10-27 | The University Of Chicago | Farnesoid x-activated receptor agonists |
US7186519B2 (en) * | 2002-11-13 | 2007-03-06 | Trustees Of Dartmouth College | Method for detecting intracellular cholesterol |
WO2005085865A2 (en) * | 2004-03-09 | 2005-09-15 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with thyroid hormone receptor beta (thrb) |
US10987362B2 (en) | 2004-03-12 | 2021-04-27 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using FXR ligands |
LT2712617T (en) | 2004-03-12 | 2017-01-25 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using Fxr ligands |
US20060041987A1 (en) * | 2004-08-24 | 2006-03-02 | Villain Susan K | Disposable underarm perspiration patch |
US20070032464A1 (en) * | 2004-10-08 | 2007-02-08 | Shutsung Liao | Methods of treating cancers |
DE602005027495D1 (en) * | 2005-03-29 | 2011-05-26 | Fujikura Kasei Kk | METHOD FOR DETECTING A SUBSTANCE BONDED TO A NUCLEAR RECEPTOR |
ITMI20050912A1 (en) | 2005-05-19 | 2006-11-20 | Erregierre Spa | PROCESS OF PREPARATION OF ACIDS 3-A-YA (B) -DIDROSSI-6-A (B) -ALCHIL-5B-COLANICI |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
WO2008091540A2 (en) | 2007-01-19 | 2008-07-31 | Intercept Pharmaceuticals, Inc. | 23-substituted bile acids as tgr5 modulators and methods of use thereof |
EP2215474A4 (en) * | 2007-07-16 | 2012-07-18 | Avaxia Biologics Inc | Antibody therapy for modulating function of intestinal receptors |
EP2725035A1 (en) | 2007-10-02 | 2014-04-30 | Avaxia Biologics, Inc. | Antibody therapy for use in the digestive tract |
CN105037476B (en) | 2008-07-30 | 2018-06-12 | 英特塞普特医药品公司 | TGR5 conditioning agents and its application method |
PT2698375T (en) | 2008-11-19 | 2018-05-25 | Intercept Pharmaceuticals Inc | Tgr5 modulators and method of use thereof |
WO2010069604A1 (en) | 2008-12-19 | 2010-06-24 | Royal College Of Surgeons In Ireland | Treatment of diarrhoea |
CN102482315A (en) * | 2009-07-29 | 2012-05-30 | 芝加哥大学 | Liver x receptor agonists |
US9982008B2 (en) | 2012-06-19 | 2018-05-29 | Intercept Pharmaceuticals, Inc. | Preparation and uses of obeticholic acid |
EA032347B1 (en) | 2012-06-19 | 2019-05-31 | Интерсепт Фармасьютикалз, Инк. | Preparation, use and solid forms of obeticholic acid |
HUE052856T2 (en) | 2013-09-11 | 2021-05-28 | Inst Nat Sante Rech Med | Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection |
JP2020515564A (en) | 2017-03-30 | 2020-05-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Methods and pharmaceutical compositions for reducing episomal virus persistence and expression |
JP2022540699A (en) | 2019-07-18 | 2022-09-16 | ウエヌイグレックオ・ファーマ | How to reduce the adverse effects of interferon |
MX2022008062A (en) | 2020-01-15 | 2022-07-27 | Inst Nat Sante Rech Med | Use of fxr agonists for treating an infection by hepatitis d virus. |
EP4277622A1 (en) | 2021-01-14 | 2023-11-22 | ENYO Pharma | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
WO2022229302A1 (en) | 2021-04-28 | 2022-11-03 | Enyo Pharma | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5071773A (en) * | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
US5582981A (en) * | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6005086A (en) * | 1995-01-13 | 1999-12-21 | The Salk Institute For Biological Studies | Farnesoid activated receptor polypeptides, and nucleic acid encoding the same |
-
2000
- 2000-01-06 WO PCT/US2000/000431 patent/WO2000040965A1/en active Application Filing
- 2000-01-06 US US09/478,948 patent/US6465258B1/en not_active Expired - Lifetime
- 2000-01-06 AU AU24096/00A patent/AU2409600A/en not_active Abandoned
-
2002
- 2002-08-12 US US10/217,293 patent/US20030003520A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5071773A (en) * | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
US5582981A (en) * | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060160111A1 (en) * | 2004-12-02 | 2006-07-20 | Vanderbilt University | Measuring forster resonance energy transfer with polarized and depolarized light |
US8031338B2 (en) * | 2004-12-02 | 2011-10-04 | Vanderbilt University | Measuring Forster resonance energy transfer with polarized and depolarized light |
US11311557B2 (en) | 2015-02-06 | 2022-04-26 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions for combination therapy |
EP4035665A1 (en) | 2015-02-06 | 2022-08-03 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions for combination therapy |
US10894054B2 (en) | 2015-04-07 | 2021-01-19 | Intercept Pharmaceuticals, Inc. | FXR agonist compositions for combination therapy |
WO2020243590A1 (en) | 2019-05-30 | 2020-12-03 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease |
Also Published As
Publication number | Publication date |
---|---|
WO2000040965A1 (en) | 2000-07-13 |
US6465258B1 (en) | 2002-10-15 |
AU2409600A (en) | 2000-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6465258B1 (en) | FXR receptor-mediated modulation cholesterol metabolism | |
US20020048572A1 (en) | Treatment of hypertriglyceridemia and other conditions using LXR modulators | |
Jiang et al. | Exclusive homodimerization of the orphan receptor hepatocyte nuclear factor 4 defines a new subclass of nuclear receptors | |
Porter et al. | Role of estrogen receptor/Sp1 complexes in estrogen-induced heat shock protein 27 gene expression. | |
Zetterström et al. | Retinoid X receptor heterodimerization and developmental expression distinguish the orphan nuclear receptors NGFI-B, Nurr1, and Nor1. | |
US5854202A (en) | Peptide fragments of calreticulin, peptide mimetics thereof, and pharmaceutical compostions comprising same | |
Yudt et al. | Molecular origins for the dominant negative function of human glucocorticoid receptor beta | |
Lee et al. | Heterodimers of retinoic acid receptors and thyroid hormone receptors display unique combinatorial regulatory properties | |
Malik et al. | TFIIB-directed transcriptional activation by the orphan nuclear receptor hepatocyte nuclear factor 4 | |
Hsu et al. | Promoter-specific trans-activation and inhibition mediated by JunB | |
US6365361B1 (en) | Method for identifying or screening agonist and antagonist to PPAR | |
US20080032961A1 (en) | Therapy employing LXRalpha modolators | |
Gay et al. | The LIM/homeodomain protein islet-1 modulates estrogen receptor functions | |
Yen et al. | Studies on the repression of basal transcription (silencing) by artificial and natural human thyroid hormone receptor-beta mutants | |
Bois-Joyeux et al. | Modulation of the far-upstream enhancer of the rat α-fetoprotein gene by members of the RORα, Rev-erbα, and Rev-erbβ groups of monomeric orphan nuclear receptors | |
Bailey et al. | Characterization and functional analysis of cAMP response element modulator protein and activating transcription factor 2 (ATF2) isoforms in the human myometrium during pregnancy and labor: identification of a novel ATF2 species with potent transactivation properties | |
US20020152479A1 (en) | Car modulators: screening and treatment of hypercholesterolemia | |
Janson et al. | Functional regulatory regions of human transcription factor MEF2C | |
Jacobson et al. | Downstream regulatory element antagonistic modulator regulates islet prodynorphin expression | |
US20040115666A1 (en) | Method for identifying compounds modulating reverse cholesterol transport | |
Farsetti et al. | Inhibition of ERα-mediated trans-activation of human coagulation factor XII gene by heteromeric transcription factor NF-Y | |
CA2140814A1 (en) | Use of calreticulin in modulating hormone responsiveness and new pharmaceuticals for treating cancer, osteoporosis and chronic inflammatory disease | |
US20040253648A1 (en) | Method for creating nuclear receptor activity modulating pharmaceuticals | |
WO2000008052A1 (en) | A novel retinal nuclear hormone receptor | |
Cheng et al. | Human chorionic gonadotropin-activated cAMP pathway regulates human placental GnRH receptor gene transcription in choriocarcinoma JEG-3 cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AMGEN SF, LLC, CALIFORNIA Free format text: CHANGE OF NAME;ASSIGNOR:ARROW ACQUISITION, LLC;REEL/FRAME:016309/0812 Effective date: 20040813 Owner name: ARROW ACQUISITION, LLC, CALIFORNIA Free format text: MERGER;ASSIGNOR:TULARIK INC.;REEL/FRAME:016309/0003 Effective date: 20040813 |
|
AS | Assignment |
Owner name: AMGEN INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AMGEN SF, LLC;REEL/FRAME:016871/0736 Effective date: 20050617 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |